header logo image


Page 718«..1020..717718719720..730740..»

Novel form of cell-free therapy revealed by researchers – Drug Target Review

January 21st, 2020 8:41 am

Researchers have developed cytochalasin B-induced membrane vesicles which they suggest could be a new form of cell-free therapy in regenerative medicine.

Work on extracellular microvesicles (ECMVs) derived from human mesenchymal stem cells (MSCs) has revealed a potential new form of cell-free therapy.

ECMVs are microstructures surrounded by a cytoplasm membrane; they have proven to be a prospective therapeutic tool in regenerative medicine due to their biocompatibility, miniature size, safety and regenerative properties. These can be used to circumvent the limitations of existing cell therapies without losing any effectiveness.

Cell therapies are grafts or implants of living tissue, such as bone marrow transplants, used to replace and regenerate damaged organ tissue. They currently have limited applications, as they work differently dependent on conditions and the environment they are placed into. They can also be rejected by the immune system.

A study at Kazan Federal University, Russia, has investigated cytochalasin B-induced membrane vesicles (CIMVs) which are also derived from MSCs and are very similar to natural ECMVs.

Proteome analysis of human MSCs and CIMVs-MSCs. Venn diagram of identified proteins MSCs and CIMVs-MSCs (A). Distribution of the identified proteins in organelles, percent of unique identified proteins (B) (credit: Kazan Federal University).

The scientists studied and characterised the biological activity of MSC-derived CIMVs. A number of biologically active molecules were found in CIMVs, such as growth factors, cytokines and chemokines; their immunophenotype was also classified.They also found that CIMVs could stimulate angiogenesis in the same way as stem cells.

The team came to the conclusion that human CIMVs-MSCs can be used for cell-free therapy of degenerative diseases. Induction of therapeutic angiogenesis is necessary for the treatment of ischemic tissue damage (eg, ischemic heart disease, hind limb ischemia, diabetic angiopathies and trophic ulcers) and neurodegenerative diseases (eg, multiple sclerosis and Alzheimers disease), as well as therapies for damage of peripheral nerves and spinal cord injury.

The group say they are continuing to research the therapeutic potential for artificial microvesicles for autoimmune diseases.

The study was published in Cells.

See the original post here:
Novel form of cell-free therapy revealed by researchers - Drug Target Review

Read More...

Xenobots are here: Tiny bio-robots inside your veins may heal you & will definitely be weaponized by West to take out bad guys – RT

January 21st, 2020 8:41 am

Peter Andrewsis an Irish science journalist and writer, based in London. He has a background in the life sciences, and graduated from the University of Glasgow with a degree in Genetics

Xenobots tiny, biological robots swarms designed by a computer are upon us. What does the birth of these strange not-quite-alive creatures mean for robotics and for us?

Mankind has been imagining advanced robot technology for a long time pop culture is full of Terminators, Cylons, and Droids. But in fact, these humanoid designs show a distinct lack of imagination. Why have we always assumed that robots would be designed to have the same basic form as us: slightly ungainly primates trotting about on two feet, perhaps even toting a gun? The latest models make that particular notion look a bit 1950s.

One such model are the fearsome xenobots unleashed by American scientiststhis week. These are biological robots less than a millimetre wide, that can move, release a payload and repair themselves. Grown from stem cells (cells that can turn into any type of body cell) that were cut into specific shapes designed by a supercomputer, they can swim inside the human body for weeks on end, working together to achieve a task.

They can walk and swim, meaning they are just one sport short of a triathlon. On top of all this, they have one more superpower Wolverines healing factor. Well, it may not be ripped from Marvel comics, but they can repair themselves without any help. And when the poor little xenobots reach the end of their short but glorious lives (are they alive?) inside your body, you can rest easy with the thought that since they are entirely organic, they will biodegrade naturally. What could be more comforting than artificial creatures dying inside your veins made of nothing but harmless African clawed frog DNA?

Jokes aside, this is an astonishing leap forward in the game of playing God. But who exactly is the Dr Frankenstein to these xenobot monsters? Unnervingly, their specific shapes they come in a range of shapes that look a bit like Tetris blocks were designed not by the clever scientists, but rather by a supercomputer.

It did this via a kind of xenobot Battle Royale, in which tons of randomly-assembled designs faced off within a simulation to cull the weakest and mutate the strongest. Some of the winning forms are c-shaped, some triangular and there is even a doughnut-shaped one with a hole in the middle. But these are just the ones that made it to the final iteration. One wonders if they could be made to form any shape, like letters of the alphabet xenobot soup could be a big hit, if only they were a bit bigger. (Besides, meat grown from frog embryos cannot be the tastiest. Silly idea anyway.)

So xenobots, in a nutshell, are a swarm of invisible genetically engineered semi-sentient robots designed by an artificial intelligence to live in the human body for days or weeks at a time, where they can survive without food and heal themselves if damaged. What could go wrong?

Well, probably nothing for now. But the arms race to develop xenobots for new applications is already underway, and militaries will certainly be eager to deploy them carrying biological weapons. The supercomputer that designed the xenobots was not available for comment.

Looking at the xenobots, I knew they were reminding me of something that I couldnt put my finger on. At last, it hit me: the little guys bear a striking resemblance, both in colour and texture, to the titular villain in the 1958 Hollywood blockbuster The Blob. The only difference being of course that blessedly, the xenobots are less than a millimetre wide, and therefore present no menace to small American towns. But what if one of the team went mad and tried to create one massive xenobot, one that could open car doors and absorb teenagers? Heres hoping the supply of African clawed frog embryo stem cells is running low in their labs. Apparently, the xenobots were named after Xenopus laevis, the frogs Latin name. Can it be a coincidence, then, that the prefix xeno-is Greek for strange, foreignor alien? Either way, it suits these new life forms perfectly.

Like this story? Share it with a friend!

Visit link:
Xenobots are here: Tiny bio-robots inside your veins may heal you & will definitely be weaponized by West to take out bad guys - RT

Read More...

Mesenchymal Stem Cells Market in 2020: Global Industry Size, Demand, Growth & Development, Trends, Insights and Forecast until 2024. How’s the…

January 21st, 2020 8:41 am

Top Research Specialist Present Completer research study here is a brilliant compilation of different types of analysis of critical aspects of the global Recycled Carbon Fiber Market. It focus on how the global Recycled Carbon Fiber market is expected to grow during the course of the forecast period, With SWOT analysis it gives a complete explanation of the strengths and weaknesses of the global Recycled Carbon Fiber Market and different players operating therein.

Global Recycled Carbon Fiber Market is estimated to reach xxx million USD in 2020 and projected to grow at the CAGR of xx% during 2020-2026. According to the latest report added to the online repository of QY Research the Recycled Carbon Fiber market has witnessed an unprecedented growth till 2019. The extrapolated future growth is expected to continue at higher rates by 2026.

GetSample Copy of Recycled Carbon Fiber Market Report Available (Including Full TOC, List of Tables & Figures, Chart)@ https://www.qyresearch.com/sample-form/form/1470072/global-recycled-carbon-fiber-market

(2020-2026) Latest Recycled Carbon Fiber Market

Additionally, organic growth of the global Recycled Carbon Fiber ,owing to increasing environmental awareness, government initiatives and technological innovation, is influencing the growth of the global Market positively. Thus, the conjoint effect of all these drivers is projected to strongly bolster the growth of the global Recycled Carbon Fiber Market in the coming years from 2020 2026.

Competitive Analysis:

The report presents the Market competitive landscape and a corresponding elaborate analysis of the most important merchandiser within the Market.

Top Competitors within the world Recycled Carbon Fiber Market:

ELG Carbon Fiber, SGL Group, CFK Valley Recycling, Vartega, Procotex, Toray (Zoltek), Karborek, Solvay, Teijin

Global Recycled Carbon Fiber Market Classifications:

Transportation Aerospace Consumer Electronics Sporting Goods Other

Global Recycled Carbon Fiber Market Applications:

Transportation Aerospace Consumer Electronics Sporting Goods Other

The ultimate motive of this Research report is to analyze the Recycled Carbon Fiber Market perspective, revealed by the industry and estimate the production sector internationally. Similarly, the Research study discovers the foremost approaches of opinion for the Recycled Carbon Fiber Market. All though, the Recycled Carbon Fiber research persists a systematic perspective to provide a professional layout of the new Market. Likewise, the report also retains the evaluation of swiftly escalating Recycled Carbon Fiber producer sectors such as:

North AmericaEuropeIndiaChinaJapanMiddle East & AfricaSouth America

Request for Customization @https://www.qyresearch.com/customize-request/form/1470072/global-recycled-carbon-fiber-market

Opportunities in the Recycled Carbon Fiber Market:

1.To strategically profile key players and comprehensively analyze their Market position in terms of ranking and core competencies, and detail the competitive landscape for Market leaders2.Comprehensive quantitative analysis of the industry is provided for the period of 2020-2026 to assist stakeholders to capitalize on the prevailing Market opportunities.3.Extensive analysis of the key segments of the industry helps in understanding the trends

Table of Contents.

Report Overview: It includes major players of the global Recycled Carbon Fiber market covered in the research study, research scope, market segments by type, market segments by application, years considered for the research study, and objectives of the report.

Global Growth Trends: This section focuses on industry trends where market drivers and top market trends are shed light upon. It also provides growth rates of key producers operating in the global Recycled Carbon Fiber market. Furthermore, it offers production and capacity analysis where marketing pricing trends, capacity, production, and production value of the global Recycled Carbon Fiber market are discussed.

Market Share by Manufacturers: Here, the report provides details about revenue by manufacturers, production and capacity by manufacturers, price by manufacturers, expansion plans, mergers and acquisitions, and products, market entry dates, distribution, and market areas of key manufacturers.

Market Forecast by Consumption: The consumption and consumption value forecasts included in this section are for the global Recycled Carbon Fiber market as well as for key regional markets.

Value Chain and Sales Analysis: It deeply analyzes customers, distributors, sales channels, and value chain of the global Recycled Carbon Fiber market.

Key Findings: This section gives a quick look at the important findings of the research study.

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from the huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become a brand of quality assurance in the consulting industry.

Read the original here:
Mesenchymal Stem Cells Market in 2020: Global Industry Size, Demand, Growth & Development, Trends, Insights and Forecast until 2024. How's the...

Read More...

Precision Health Informatics and Concerto HealthAI to Collaborate on Advanced Precision Medicine Solutions – Yahoo Finance

January 20th, 2020 5:49 am

Concerto HealthAI's Real-World Data analytical capabilities will enable Precision Health Informatics to accelerate innovation in cancer testing and treatment

DALLAS and BOSTON, Jan. 14, 2020 /PRNewswire-PRWeb/ --Concerto HealthAI, the market leader for Real-World Data (RWD) and enterprise AI technology, announced today an agreement with Precision Health Informatics, a subsidiary of community-based cancer care pioneer Texas Oncology, to accelerate the advancement of precision medicine to treat cancer patients. Precision Health Informatics will work with Concerto HealthAI to advance RWD solutions, research studies, and AI-enabled technologies focusing on genomic and molecular characterization of patient disease to develop effective new therapies to treat some of the most challenging and devastating cancers.

Precision Health Informatics will leverage Concerto HealthAI's eurekaHealth 3.0 enterprise AI solution to advance precision medicine solutions for clinical research. Using AI models to enrich clinical data, Precision Health Informatics will more quickly derive insights from patient data to inform new study designs or identify eligible patients for clinical studies. Precision Health Informatics joins an expanding set of Concerto HealthAI's Real-World Evidence collaborators, such as theAmerican Society of Clinical Oncology's CancerLinQ relationship announced in late 2017.

"Precision Health Informatics' model uses information from the molecular profile representing the genetics of the patient's disease combined with the clinical information specific to that patient to develop personalized medicine solutions that are integral to diagnosing cancer and offering physicians and patients effective treatment options," said Lori Brisbin, Vice President for Precision Health Informatics, "Concerto HealthAI's leadership in solutions for precision medicine will help us derive more meaningful insights from patient data, that in turn may help us connect patients with appropriate clinical trials."

"Using data from Texas Oncology's large patient base, Precision Health Informatics is at the forefront of precision medicine, innovative cancer testing and diagnostic approaches, such as Next Generation Sequencing changing and improving the standard of care for patients. Ultimately, this is all about developing and connecting cancer patients to precise, effective treatment," said R. Steven Paulson, MD, President of Precision Health Informatics, and President and Chairman of Texas Oncology. "Concerto HealthAI's deep expertise in research-grade RWD solutions and AI technologies make it the ideal collaborator with Precision Health Informatics to help us more quickly develop medical innovations that benefit patients in our practice and elsewhere."

"At Concerto HealthAI, we seek clinical collaborators committed to advancing insights and new treatment strategies for patients with the highest unmet medical needs," said Jeff Elton, PhD, CEO of Concerto HealthAI. "Precision Health Informatics is making a deep commitment to enabling precision medicine, which we see as highly complementary to the work of our biomedical innovator partners."

This collaboration will advance novel research solutions, integrating deep clinical insights derived from electronic medical record data, particularly information about the molecular basis of disease derived from tissue or liquid samples. The value of these insights in helping connect patients to effective treatment options will be made available to Texas Oncology patients through its precision medicine program.

About Concerto HealthAI Concerto HealthAI is a technology leader in Definitive Real-World Data (RWD) and AI solutions for Precision Oncology. Our mission is to bring together unique data assets, leading AI-based technologies, and the world's top outcomes research and data science talent. Our focus is on revolutionizing clinical and outcomes research to accelerate the insights benefitting patient treatment. For more information, visit us at http://www.concertohealthai.com.

About Precision Health Informatics and Texas Oncology Precision Health Informatics, a subsidiary of Texas Oncology, is a precision medicine solutions company that uses patients' genetic information for innovative testing, diagnostics, and treatment of cancer. Precision Health Informatics' solutions are based on data-driven insights from a vast, diverse patient base. Texas Oncology is an independent private practice with more than 460 physicians and 210 locations across the state. Meeting the oncology needs of Texans for more than 35 years, the practice includes Texas Center for Proton Therapy, Texas Breast Specialists, Texas Oncology Surgical Specialists, and Texas Center for Interventional Surgery. As a lead participant in US Oncology Research, Texas Oncology played a role in the development of more than 90 FDA-approved therapies, about one-third of all cancer therapies approved to date. For more information, visit http://www.texasoncology.com.

MEDIA CONTACTS

Jen Toole Concerto HealthAI 617.779.1828 jtoole@shiftcomm.com

Ed Bryson Texas Oncology 512.592.8190 edward.bryson@usoncology.com

SOURCE Concerto HealthAI

More here:
Precision Health Informatics and Concerto HealthAI to Collaborate on Advanced Precision Medicine Solutions - Yahoo Finance

Read More...

Moderna Partners with AWS to Explore the ‘Software of Life’ – BioSpace

January 20th, 2020 5:49 am

The software of life. Thats how Stephane Bancel, the chief executive officer of Moderna, described messenger RNA (mRNA), which is at the core of Modernas drug development process.

Moderna is pioneering mRNA drugs that are believed to be able to direct the body to produce any protein of interest, including antibodies and other proteins that can create therapeutic activity. Bancel said mRNA is an information molecule.

Its like software, he said.

The company, which has secured enormous investments over the past few years, is inching closer to being a commercial company in developing personalized therapies for a wide range of diseases, including cancer. In order to create those personalized medicines, the Cambridge, Mass.-based company relies on gene sequencing and a partnership with one of the worlds largest companies Amazon.

In an interview with CNBCs Jim Cramer during the J.P. Morgan Healthcare Conference this week, Bancel said the company relies on Amazon Web Services to compare every letter of DNA in the sequencing process. Once that is done, the company can deduce what needs to be done to develop personalized medicine, Bancel explained.

Amazon Web Services, the fastest growing division of the company, according to CNBC, provides on-demand cloud computing platforms to companies. Moderna is currently using Amazon Web Services with more than a dozen drug candidates in its pipeline, which means the high-tech platform plays a central role in the companys drug development program. As CNBC explains, the company is using the powerful cloud-based service to speed up the time it takes a drug candidate to move from the preclinical to the clinical phase. In addition to Moderna, Amazon Web Services is being used by several pharmaceutical companies, including San Diego-based Human Longevity Inc., Regeneron Pharmaceuticals and more.

The reliance on the high-speed program could lead to the company finally becoming a commercial entity 10 years after it was launched. Last week, just ahead of JPM, Bancel pointed to one of the companys clinical candidates as a potential blockbuster, an experimental treatment for cytomegalovirus (CMV), the most common infectious cause of birth defects in the United States.

Moderna said the analysis following a Phase I trial, which was taken after the third and final vaccination, shows continued boosting of neutralizing antibody titers in patients. The mRNA-based vaccine, mRNA-1647, is designed to protect against CMV infection. Cytomegalovirus is a common pathogen and is the leading infectious cause of birth defects in the United States with approximately 25,000 newborns in the U.S. infected every year. CMV is passed from the mother to her unborn child. Birth defects occur in about 20% of infected babies. The defects can include neurodevelopmental disabilities such as hearing loss, vision impairment, varying degrees of learning disability and decreased muscle strength and coordination. There is no approved vaccine to prevent CMV infection.

In October, the company received Fast Track Designation from the U.S. Food and Drug Administration for mRNA-3927, its investigational mRNA therapeutic for propionic academia, which is caused by the inability of the body to breakdown certain proteins and fats which leads to the build-up of toxic chemicals. Moderna plans to initiate an open-label, multi-center, dose-escalation Phase I/II study of multiple ascending doses of mRNA-3927 in primarily pediatric patients.

Read the original:
Moderna Partners with AWS to Explore the 'Software of Life' - BioSpace

Read More...

Is Cloud Computing the Answer to Genomics Big Data… – Labiotech.eu

January 20th, 2020 5:49 am

The success of the genomics industry has led to generation of huge amounts of sequence data. If put to good use, this information has the potential to revolutionize medicine, but the expense of the high-powered computers needed to achieve this is making full exploitation of the data difficult. Could cloud computing be the answer?

Over the last decade, genomics has become the backbone of drug discovery. It has allowed scientists to develop more targeted therapies, boosting the chances of successful clinical trials. In 2018 alone, over 40% of FDA-approved drugs had the capacity for being personalized to patients, largely based on genomics data. As the percentage has doubled over the past four years, this trend is unlikely to slow down anytime soon.

The ever-increasing use of genomics in the realm of drug discovery and personalized treatments can be traced back to two significant developments over the past decade: plunging sequencing costs and, consequently, an explosion of data.

As sequencing technologies are constantly evolving and being optimized, the cost of sequencing a genome has plummeted. The first sequenced genome, part of the Human Genome Project, cost 2.4B and took around 13 years to complete. Fast forward to today, and you can get your genome sequenced in less than a day for under 900.

According to the Global Alliance for Genomics and Health, more than 100 million genomes will have been sequenced in a healthcare setting by 2025. Most of these genomes will be sequenced as part of large-scale genomic projects stemming from both big pharma and national population genomics initiatives. These efforts are already garnering immense quantities of data that are only likely to increase over time. With the right analysis and interpretation, this information could push precision medicine into a new golden age.

Are we ready to deal with enormous quantities of data?

Genomics is now considered a legitimate big data field just one whole human genome sequence produces approximately 200 gigabytes of raw data. If we manage to sequence 100M genomes by 2025 we will have accumulated over 20B gigabytes of raw data. The massive amount of data can partially be managed through data compression technologies, with companies such as Petagene, but that doesnt solve the whole problem.

Whats more, sequencing is futile unless each genome is thoroughly analyzed to achieve meaningful scientific insights. Genomics data analysis normally generates an additional 100 gigabytes of data per genome for downstream analysis, and requires massive computing power supported by large computer clusters a feat that is economically unfeasible for the majority of companies and institutions.

Researchers working with large genomics datasets have been searching for other solutions, because relying solely on such high-performance computers (HPC) for data analysis is economically out of the question for many. Large servers require exorbitant amounts of capital upfront and incur significant maintenance overheads. Not to mention, specialized and high-level hardware, such as graphics processing units, require constant upgrades to remain performant.

Furthermore, as most HPCs have different configurations, ranging from technical specs to required software, the reproducibility of genomics analyses across different infrastructures is not a trivial feat.

Cloud computing: a data solution for small companies

Cloud computing has emerged as a viable way to analyze large datasets fast without having to worry about maintaining and upgrading servers. Simply put, Cloud computing is a pay-as-you-go model allowing you to rent computational power and storage. and its pervasive across many different sectors.

According to Univa the industrial leader in workload scheduling in the cloud and HPC more than 90% of organizations requiring high performance computing capacity have moved, or are looking into moving to the cloud. Although this is not specific for companies in the life sciences, Gary Tyreman Univas CEO suggests that pharmaceutical companies are ahead of the market in terms of adoption.

The cloud offers flexibility, an alluring characteristic for small life science companies that may not have the capital on-hand to commit to large upfront expenses for IT infrastructure: HPC costs can make or break any company. As a consequence, many opt to test their product in the cloud first, and if numbers look profitable, they can then invest in an in-house HPC solution.

The inherent elasticity of cloud resources enables companies to scale their computational resources in relation to the amount of genomic data that they need to analyze. Unlike with in-house HPCs, this means that there is no risk money will be wasted on idle computational resources.

Elasticity also extends to storage: data can be downloaded directly to the cloud and removed once the analyses are finished, with many protocols and best practices in place to ensure data protection. Cloud resources are allocated in virtualized slices called instances. Each instance hardware and software is pre-configured according to the users demand, ensuring reproducibility.

Will Jones, CTO of Sano Genetics, a startup based in Cambridge, UK, offering consumer genetic tests with support for study recruitment, believes the cloud is the future of drug discovery. The company carries out large data analyses for researchers using its services in the cloud.

In a partnership between Sano Genetics and another Cambridge-based biotech, Joness team used the cloud to complete the study at a tenth of the cost and in a fraction of the time it would have taken with alternative solutions.

Besides economic efficiency, Jones says that moving operations to the cloud has provided Sano Genetics with an additional security layer, as the leading cloud providers have developed best practices and tools to ensure data protection.

Why isnt cloud computing more mainstream in genomics?

Despite all of the positives of cloud computing, we havent seen a global adoption of the cloud in the genomics sector yet.

Medley Genomics a US-based startup using genomics to improve diagnosis and treatment of complex heterogeneous diseases, such as cancer moved all company operations to the cloud in 2019 in a partnership with London-based Lifebit.

Having spent more than 25 years at the interface between genomics and medicine, Patrice Milos, CEO and co-founder of Medley Genomics, recognized that cloud uptake has been slow in the field of drug discovery, as the cloud has several limitations that are preventing its widespread adoption.

For starters, long-term cloud storage is more expensive than the HPC counterpart: cloud solutions charge per month per gigabyte, whereas with HPC, once youve upgraded your storage disk, you have no additional costs. The same goes for computing costs: while the cloud offers elasticity, Univas CEO Tyreman says that the computation cost of a single analysis is five times more expensive compared to an HPC solution in many scenarios. However, as cloud technologies continue to progress and the market becomes increasingly more competitive among providers, the ongoing cloud war will likely bring prices down.

Furthermore, in the world of drug discovery, privacy and data safety are paramount. While cloud providers have developed protocols to ensure the data is safe, some risks still exist, for example, when moving the data. Therefore, large pharmaceutical companies prefer internal solutions to minimize these risks.

According to Milos, privacy remains the main obstacle for pharmaceutical companies to fully embrace the cloud, while the cost to move operations away from HPCs is no longer a barrier. While risks will always exist to a certain extent, Milos highlighted that the cloud allows seamless collaboration and reproducibility, both of which are essential for research and drug discovery.

Current players in the cloud genomics space

Cloud computing is a booming business and 86% of cloud customers rely on three main providers: AWS (Amazon), Azure (Microsoft) and Google Cloud. Although the three giants currently control the market, many other providers exist, offering more specialized commercial and academic services.

Emerging companies are now leveraging the technology offered by cloud providers to offer bioinformatics solutions in the cloud, such as London-based Lifebit, whose technology allows users to run any bioinformatics analyses through any cloud provider with a user-friendly interface effectively democratizing bioinformatics for all researchers, regardless of skill set.

Federation is a concept from computing now used in the field of genomics. It allows separate computers in different networks to work together to perform secure analysis without having to expose private data to others, effectively removing any potential security issues.

The amount of data organizations are now dealing with has become absolutely unmanageable with traditional technologies, and is too big to even think about moving, explained Maria Chatzou Dunford, Lifebits CEO and co-founder.

When data is moved, you increase the chances of having it be intercepted by third-parties, essentially putting it at significant risk. Data federation is the only way around this unnecessary data storage and duplication costs, and painstakingly slow data transfers become a thing of the past.

Getting ready for the genomics revolution

Its no secret that genomics is key to enabling personalized medicine and advancing drug discovery. We are now seeing a genomics revolution where we have an unprecedented amount of data ready to be analyzed.

The challenge now is: are we ready for it? To be analyzed, big data requires massive computation power, effectively becoming an entry barrier for most small organizations. Cloud computing provides an alternative to scale analyses, while at the same time, facilitating reproducibility and collaboration

While the cost and security limitations of cloud computing are preventing companies from fully embracing the cloud, these drawbacks are technical and are expected to be resolved within the next few years.

Many believe that the benefits of the cloud heavily outweigh its limitations. With major tech giants competing to offer the best cloud solutions a market valued at $340 billion by 2024 we might be able to expect a drastic reduction in costs. While some privacy concerns may still exist, leading genomics organizations are developing new tools and technologies to protect genomic data.

Taken as a whole, it is likely that the cloud will be increasingly important in accelerating drug discovery and personalized medicine. According to Univas Tyreman, it will take around 1015 years to see the accelerated transition from HPC to cloud, as large organizations are often conservative in embracing novel approaches.

Distributed big data is the number one overwhelming challenge for life sciences today, the major obstacle impeding progress for precision medicine, Chatzou Dunford concluded.

The cloud and associated technologies are already powering intelligent data-driven insights, accelerating research, discovery and novel therapies. I have no doubt we are on the cusp of a genomics revolution.

Filippo Abbondanza is a PhD candidate in Human Genomics at the University of St Andrews in the UK. While doing his PhD, he is doing an internship at Lifebit and is working as marketing assistant at Global Biotech Revolution, a not-for-profit company growing the next generation of biotech leaders. When not working, he posts news on LinkedIn and Twitter.

Images via E. Resko, Lifebit and Shutterstock

See the article here:
Is Cloud Computing the Answer to Genomics Big Data... - Labiotech.eu

Read More...

Leadership in the Age of Personalization is About Creating Healthy Environments So People Can Thrive – Forbes

January 20th, 2020 5:49 am

This is Part 8 of an eight-part series featuring thought-provoking insights from theLeadership in the Age of Personalization Summit. Here is Part 1, Part 2, Part 3, Part 4, Part 5, Part 6 and Part 7.

All Employers are in the Business of Health

My definition of harmony is when your head, your heart, your feet, and your gut are all going in the same direction.

I love that quote. In the context of business, we could think of the head as your strategy, the heart as your vision, the feet as your operating model and forgive the metaphor the gut as your source of fuel. Its where your resources churn and create the energy that makes everything else possible.

In other words, its your people.

Are your head, heart, feet and gut in harmony? Or, more likely, is your gut a little upset? Off balance? Irritated?

Think about how difficult it is to get anything done when your actual, physical gut is irritated. A large organization is the same. You can have a bold vision, a smart strategy, an effective operating model. But if your people are feeling stifled, not activated to their fullest potential, or bogged down by physical, emotional or financial health issues, none of that other stuff will make a difference.

In my last article, part 7 of this series, we heard from healthcare leaders. But the reality is were all in the business of health. No matter your industry, the physical, mental and financial health of your employees and their families affects your bottom line and your ability to thrive as an organization. The health of your customers and the communities you serve also affect the scope of the impact you can have.

How does this fit into this series of articles on our societys transition from an age of standardization to our current age of personalization? Heres a story that might help connect the dots.

A few years ago I met with some C-level executives at a company. I made a bold prediction: You probably have someone at the executive level who has a chronic disease or cares for someone with a chronic disease that is not covered by your insurance. They're probably struggling to get by, even with an executive salary."

Most respectfully disagreed with my prediction. But one person at the table scribbled a note and the CEO said: "Looks like I'm wrong." There was a VP who was living out of his car because he was paying for his mother's cancer and a grandparents diabetes.

If were leading in a way that honors this age of personalization, everything about that scenario should change. Ill leave it to the experts to fix our system so caring for sick family members wont cost so much. But we can at least we can create workplace cultures that dont make someone feel like they must hide such hardships from their peers.

We need systems in place for getting to know people as individuals. People shouldnt be afraid to discuss health issues related to physical or mental health. If they are afraid, youve got a problem.

In its Mental Health at Work 2019 Report, Mind Share Partners shares results from surveying 1,500 people in the United States: nearly 60% of respondentsreported symptoms of a mental health condition in the past year; and almost 60% of people never talked to anyone at work about their mental health in the last year. No wonder: when conversations about mental health did occur, less than half were described as a positive experience. One result? Youll lose good people. According to the survey, 50% of millennials, 75% of Gen Z-ers and 34% overall had left roles for mental health reasons, both voluntarily and involuntarily.

How do we as leaders open ourselves up so that people will be comfortable to be in their most vulnerable state?

This subject was tackled at the Leadership in the Age of Personalization Summit, where senior leaders from industries spanning healthcare, automotive, finance, consumer packaged goods, retail, technology, apparel and more, gathered to explore the tension were all feeling in this shift from standardization to personalization.

Throughout the day we discussed building economies of scale around human dignity, how to escape the extremes to achieve balance, how assimilation destroys individuality and inclusion restores it, how to allow personalized values to influence your brand identity, Wall Streets perspective on how companies are not prepared for what is about to hit them, how a companys mission is worthless without individual contribution and the importance of what you measure.

Tending to Employees Mental Health

Stephanie Neuvirth is the Senior Vice President of People and Organization at Banfield Pet Hospital.

She said Banfields people strategy is its business strategy, because to keep growing as a company they need to attract and retain more healthcare professionals a goal made more challenging by the cost of veterinary school and high levels of compassion fatigue among practitioners.

The pet space is growing at double digit growth, she said. As we look at the growth of our business and the trajectory over the next 10 years, and then look at the supply of the individuals in our space, candidly, the biggest concern to our growth strategy is our ability to find and keep great talent.

Stephanie Neuvirth and Gyasi Chisley during their panel discussion at the Leadership in the Age of ... [+] Personalization Executive Summit.

Banfield leaders believe theres a connection between Banfields commitment to preventive health for pets and its commitment to the health and energy of employees (whom they call associates). They deal with many of the same challenges as people in human healthcare do.

We see very high levels of compassion fatigue, high levels of suicide, high levels of burnout, said Neuvirth. What we see is a very serious and concerning situation about the profile of the individuals that go into our profession. They tend to be perfectionists. They are burdened with tremendous student debt. All of these things combined make it a very, very challenging environment.

Banfields health & wellbeing approach encompasses five areas: body, mind, finances, career and community.

We believe that all five parts are very important, and it's a different combination for every single person, said Neuvirth. For some, their biggest stressor is financial. For others its about not feeling connected to community. For others, it really is about not getting the career growth that they're looking for. So we're focused on how we bring all five parts to life and how to solve for the various combinations.

Ive written in the past about Banfields Veterinary Student Debt Relief Program (read about it here): Managing Employee Stress, Debt, and Emotional Turmoil in the Age of Personalization.

The nations largest general veterinary practice is also putting particular attention and resources behind mental health, addressing the suicide epidemic head-on.

According to the CDC, one in six veterinarians has considered suicide, said Neuvirth. Those are staggering and very concerning numbers. In 2018, we hired a mental health professional and are looking at partnering with social workers, not just for our client experience but for our associates.

She said they recently rolled out a first-of-its kind suicide prevention training for veterinary professionals called ASK Assess, Support, Know.

ASK is intended not only to support our own associates, but also to give them tools to spot emotional distress and suicidal thoughts in their colleagues, she said. In addition to making the ASK e-learning available to all 19,000+ Banfield associates nationwide, we also closed schedules at all of our 1,000+ Banfield hospitals for two hours to offer an interactive mental health and wellbeing training.

And theyre sharing the ASK training and resources with the industry.

As one of the largest employers in the veterinary health space, we feel a responsibility to support the entire profession, said Neuvirth. In observance of the harrowing 1-in-6 statistic, we made ASK available to the entire profession, including U.S. vet schools, on January 6, 2020.

That last part is so important: finding creative solutions and then sharing them with others.

In past articles Ive talked about discovering what you solve for as an individual what you solve for is what you consistently think about in a big way, the problems you are typically drawn to, and the kinds of solutions you favor. But it also applies to organizations.

One of the things Banfield is solving for is suicide awareness and prevention among healthcare professionals, and theyve created a method that can be used by others facing similar challenges. This is what can happen when you start tending to your gut and put individuals at the center of your strategy.

Making Cancer Care More Precise

Going back to healthcare in particular, one of our biggest challenges is to make sure our increasing levels of personalized care are accessible to all people. Next Ill share the personalization of cancer care from the viewpoint of a physician providing the care and then an executive of an organization expanding access to care.

Dr. Joseph Alvarnas is Vice President of Government Affairs, Senior Medical Director for Employer Strategy, and Associate Clinical Professor in the Department of Hematology/Hematopoietic Cell Transplantation at City of Hope.

He described how this tension between personalization and standardization has actually changed paradigms of care.

I'm a cancer care provider, he said. We've entered an era of precision medicine. So, things that we would have thought about as one cancer a decade ago when you look at them very closely on a genetic level, you realize they represent hundreds of different of sub-types of cancer.

He said there are about 22,300 genes in the human genome.

That's the entire instruction set to make, maintain, sustain a human being over the course of our lives, he said. Sometimes those genes go wrong in very, very particular ways. We're learning about these things at a pace that I would never have imagined years ago, and we're seeing innovations directed at very specific genetic mutations in cancer.

Dr. Alvarnas speaks at the Leadership in the Age of Personalization Executive Summit.

This idea that we can understand the genetic nature of someone's cancer, identify the exact correct therapeutic, and bring it to that individual in a timely, efficient, rapid way, said Dr. Alvarnas, so that we don't give wrong care, we mitigate unnecessary toxicities, we get that person well, keep them home, get them back to life that's actually real. That's the precision and personalized medicine paradigm for delivering care.

Talk about personalization. But he also posed this challenge: How do you create a system of high through-put knowledge understanding, and then marshal it to the needs of a patient in a family in a highly personalized way?

Because cancer care is not a technological experience, it's a human experience, said Dr. Alvarnas. We don't treat diseases. We care for patients and their families, because families are as responsible for good outcomes as any of the most critical elements of what we do.

Then he made the connection to employers.

Employers are invested in this, because not only do employers bear the costs for misadventures in care, but they also bear witness to the human consequences of what it's like to have an employee or a family member, or someone who's aligned with your company, go through a cancer journey.

Making Cancer Care More Accessible

Just as each cancer is different, so is each persons cancer journey.

Gyasi Chisley is another healthcare executive working hard to make those journeys as personalized as possible. He is President of Hospitals and Clinics for Cancer Treatment Centers of America (CTCA), a national comprehensive cancer care network with five hospitals around the country and a growing footprint of Outpatient Care Centers and other locations.

CTCA has been around for about 32 years, and its founder Richard J. Stephenson had the notion of creating a patient empowerment platform. Chisley said 82% of their patients live below the Federal Poverty Line. He said consumers come directly to them, usually for a second opinion, which means theyre often out-of-network.

A lot of the folks that were suffering from cancer or had that evil diagnosis were, number one, scared, and then number two, didn't have an opportunity to get that second opinion, said Chisley. So we started expanding through a footprint of what we call OIS, which is Oncology Information Systems just to get information out there directly to the patient. And that's been happening for 32 years.

They also took a holistic approach.

Our chairman had the foresight to say let's treat the patient holistically, with things like massage and acupuncture almost regardless of cost because we think thats better in the long run, said Chisley. But even more, what are the patient's goals? What are they really trying to achieve?

Chisley said one of the things theyre working on is going direct to employer, and having those crucial conversations with employers that will help them look at their workforce planning and look for opportunities for interventions that will ensure that the continuum of care is top of mind.

Glenn Llopis and Gyasi Chisley during their fireside chat at the Age of Personalization Executive ... [+] Summit.

We're not the most popular people in the payer's eyes these days we're doing things like having diet consults, we're doing things that are out of the box, if you will, for new cutting-edge clinical trials, and not always getting reimbursed from the payer, said Chisley. But you know what that is demonstrating? It's demonstrating to the employer that we're taking care of their people, and that's why we're going direct to employer and direct to consumer. So, that's opportunity for us, not only to be evolutionary, but revolutionary.

Chisley said after a day of hearing executives talk about personalization at the summit, hes inspired to dig even deeper as a leader: We see our patients come in at their most vulnerable times, particularly with this despicable disease of cancer. I've been vulnerable, but I haven't been vulnerable enough. And that's opportunity for me to be humble and make sure we're meeting our patients where they are.

An Appeal From Gen Z

Meeting people where they are. Thats what this age of personalization is all about.

After a full day of C-level leaders sharing their experiences and being vulnerable with each other, we closed the summit with a different kind of VIP your current customer, your future employee and, frankly, your future leader.

Brielle Lubin is in 8th grade. She describes herself as born from a Jewish-American father and a Japanese mother from Tokyo. She is very proud of her Jewish-American culture and is equally proud of her Japanese culture. At her school in Los Angeles she leads two clubs: the Gender Sexuality Awareness Club and the Asian American Cultural Club.

Throughout the day of the summit, she had been playing piano in the background. When she addressed the audience from the stage at the end of the day, she did it with the confidence of someone who already gives thought and action to these ideas of personalization.

Heres just a sampling of what she shared with us:

As a part of the youth community, we're always told, You have no idea what you're talking about. That's so ridiculous. That's frivolous. You're too young.

I may not be the CEO of a company like everyone else here. I'm just some 14-year-old kid. But you know what? When we're told when we're younger, Hey, you can be yourself, you can express your opinion, there are places where people can talk to you and help you I find that to be the most important thing. Because we cannot start assimilating when were young, if [our goal is to] avoid assimilating when we're older.

Brielle Lubin speaks at the Leadership in the Age of Personalization Executive Summit.

Everyone is a different shade of a color in the entire color spectrum. None of us is exactly the same. There's always some sort of shade that's just a little bit off, and that's the most important thing and we need to acknowledge that because identity crisis occurs the most when we don't recognize that difference, when we think we need to blend with other colors.

When people try to paint something, they don't just blend every single color of the rainbow together. They use all the colors individually, use them as a different shade on a different part of the paper, and that's what we are. We are all that different shade of a color on that paper.

Welcome to the Age of Personalization

Consider what Brielle said. This is the thinking thats already entering your workforce today, and will be in full force within your organizations in the next 10 years.

If youre not already trying to create the systems that allow for this level of inclusive leadership, you will not remain relevant in a marketplace where consumers and employees value their individuality.

The luxury of time is over, and I want to leave you with this sense of urgency. Throughout this series we have explored the difference between leadership in the age of standardization and in the age of personalization. But this is just the beginning.

Knowing something is right isnt enough to start doing it. And knowing something is wrong isnt enough to stop doing it.

We are a nation burning out at work not just because were working so hard and so much, but because were doing that without any sense of who we are and any connection to what we are doing. Engaged or not, the negative forces of standardization have stripped so many of us of our identities.

Only by rediscovering who we are as individuals and embracing that individuality in others can we find our purpose and contribute to a healthier whole.

Leadership in the age of personalization is about creating healthy environments we can all thrive in. It is the force that will push us to start over again. I see this as the beginning of a movement. And now the question is: what are you going to do about it?

Read more from the original source:
Leadership in the Age of Personalization is About Creating Healthy Environments So People Can Thrive - Forbes

Read More...

Scientists Discover 4 Distinct Patterns of Aging – Livescience.com

January 20th, 2020 5:49 am

Some people's hearts stay strong well into their 60s, but their kidneys begin to fail. Others may have the kidneys of a 30-year-old but fall victim to constant infection.

Now, scientists may be one step closer to understanding why the aging process varies so drastically between people.

Even within a single person, aging unfolds at different rates in different tissues, sometimes striking the liver before the heart or kidney, for example. People fall into distinct categories depending on which of their biological systems ages fastest, and someday, doctors could use this information to recommend specific lifestyle changes and design personalized medical treatments, according to a new study, published Jan. 13 in the journal Nature Medicine.

The research team behind the study sorted 43 people into aging categories, or "ageotypes," based on biological samples collected over the course of two years. The samples included blood, inflammatory substances, microbes, genetic material, proteins and by-products of metabolic processes. By tracking how the samples changed over time, the team identified about 600 so-called markers of aging values that predict the functional capacity of a tissue and essentially estimate its "biological age."

So far, the team has identified four distinct ageotypes: Immune, kidney, liver and metabolic. Some people fit squarely in one category, but others may meet the criteria for all four, depending on how their biological systems hold up with age.

"Now, it's going to be a lot more than just four categories," said senior author Michael Snyder, a professor and the chair of genetics at the Stanford University School of Medicine in California. For instance, one participant in the study appeared to be a cardiovascular ager, meaning their cardiac muscle accumulates wear-and-tear at a greater rate than other parts of their body. "If we [surveyed] 1,000 people, I'm sure we'll find other cardio agers and that category will become better defined." And with more research, even more patterns of aging may emerge, Snyder added.

Related: 8 Tips for Healthy Aging

In the past, scientists have hunted for markers of aging in enormous datasets for large populations, Snyder, told Live Science. Researchers pinpointed markers of aging by comparing data from young people to that of older people, but for individuals, that kind of data captures only a specific moment in time. It cannot reveal how a given person might change as they age, Snyder said.

In a clinical setting, that means population-based markers might not be the best measure to determine how a patient is aging, or what combination of medical treatments might suit them best, he added.

"Population-based decisions are crude at best," Synder said. They won't necessarily hold up for you, per se."

By tracking specific people through time, Snyder and his co-authors hoped to learn how aging markers differ between individuals. Their study participants ranged in age from 29 to 75 and provided at least five biological samples over the course of two years. Even within that relatively short time frame, several patterns of aging emerged.

For example, immunological agers accumulated more markers of inflammation through time, while metabolic agers accrued more sugar in their blood, indicating that their bodies were metabolizing glucose less efficiently. Similar to scores on a personality test, each individual's aging "profile" included a combination of traits, mixed and matched from different ageotypes.

Snyder and his co-authors plan to follow the study participants to see how their aging profiles morph over time. They also aim to develop a simple ageotype test that could be used in the doctor's office to quickly assess a patient's health status, and potentially point them toward the best possible treatment options.

"There are drugs and various kinds of dietary interventions and lifestyle interventions through which it may be possible to modulate some of these aging processes," Dr. James Kirkland, a gerontologist and head of the Kogod Center on Aging at the Mayo Clinic in Rochester, Minnesota, told NBC News.

"But in order to apply those correctly, we have to know which people to apply which drugs or which dietary interventions in order to get the most bang for the buck," said Kirkland, who was not involved in the new study.

Related: 7 Ways the Mind and Body Change With Age

While existing drugs, diets and exercise regimes can target some signs of aging, other markers aren't fully understood yet.

For example, over the course of Snyder's study, a marker of poor kidney function decreased in 12 individuals, eight of whom took statins. The marker, a waste product called creatinine, accumulates in the blood as muscle tissue naturally breaks down, but the kidneys typically filter the substance and expel it through the urine. Creatinine levels fell in the eight individuals on statins, suggesting that the medication improved their kidney function, though it's unclear why levels also dipped in four additional people, the authors noted.

The team also found that concentrations of several microbes seem to change with age, but we don't yet know how that may affect health. Certain microbes may proliferate in response to age-related changes in the body, while others help drive them, Snyder said. The authors also spotted differences in how diabetic and pre-diabetic people aged as compared to insulin-sensitive people, but it's unclear whether these markers indicate meaningful differences in health status. Many studies suggest that insulin plays a central role in aging throughout the animal kingdom, but more research is needed to clarify its exact influence over human aging.

For now, ageotypes present as many questions as they do answers about human aging. Until scientists understand what various aging markers really mean, clinicians will continue to rely on standard vital sign assessments to track patients' health over time. In the near future, perhaps ageotypes could serve to motivate people to take better care of areas of their body that appear to be aging faster than others, Snyder said. For instance, if someone fits the profile of a cardiovascular ager, they might focus on improving their cardiovascular health and undergoing relevant medical tests to check on their progress.

"As we collect a lot more information, we are going to be better able to follow how people are aging, [as well as] what interventions they did that actually reduced their aging," Snyder said.

Originally published on Live Science.

The rest is here:
Scientists Discover 4 Distinct Patterns of Aging - Livescience.com

Read More...

Artificial Intelligence Expert Neil Sahota Says AI Will Have Major Impact On 2020 Elections And In Medicine – Yahoo Finance

January 20th, 2020 5:49 am

Sahota Offers AI Predictions for the New Year

LOS ANGELES, Jan. 15, 2020 /PRNewswire/ --Artificial intelligence, or AI, will play a significant role in the 2020 election campaign and may also lead to major breakthroughs in solving personal medical issues, according to futurist and AI expert Neil Sahota.

"I'm increasingly concerned about the impact of fake news, photo scams and other deceits designed to negatively influence voting this year," says Sahota, who works closely with the United Nations and other organizations to foster innovation and develop next generation products/solutions to be powered by AI. "We will see the effect of more AI tools generating fraudulent information and influencing voters. Thankfully, there will also be new tools to fight this kind of disinformation. What is certain is that machine vs machine battles will become more prevalent."

The author of the influential book Own the AI Revolution (McGraw Hill), Sahota is also an IBM Master Inventor, who led the IBM Watson Group and is a professor at the University of California/Irvine.

In addition to its potential impact on the election campaigns, Sahota predicts AI will be responsible for significant medical advances. "We will see more use of AI that will accelerate solutions for doctors, nurses, clinicians and researchers in providing personalized care," he said. "Each of us is genetically unique and there isn't a one-size fits all solution for us. But AI can solve this dilemma by providing personalized medicine based on a specific person's genomic sequence, lifestyle, medical history, environment and other differences. I think there will be great strides in these areas in the coming year."

"The election and medicine are only two areas where we will feel the impact of AI, which is coming into its own as an emerging technology," Sahota says. "We are likely to see it help combine tools such as block chain, virtual reality and artificial reality. For example, I envision a virtual reality courtroom where a law student interacts with an AI 'judge,' opposing counsel and jury. AI simulation is not only more 'real world' but has great variability, meaning each time the VR module is used, it's different. There's no memorization or 'cheat sheet' for the law student. It's a dynamic, highly interactive learning module and 2020 will start the wave of convergence: combining these technologies together.

About Neil Sahota: Neil Sahota is a futurist and leading expert on Artificial Intelligence (AI) and other next generation technologies. He is the author of Own the AI Revolution (McGraw Hill) and works with the United Nations on the AI for Good initiative. Sahota is also an IBM Master Inventor, former leader of the IBM Watson Group and professor at the University of California/Irvine. His work spans multiple industries, including legal services, healthcare, life sciences, retail, travel, transportation, energy, utilities, automotive, telecommunications, media, and government.

View original content:http://www.prnewswire.com/news-releases/artificial-intelligence-expert-neil-sahota-says-ai-will-have-major-impact-on-2020-elections-and-in-medicine-300987177.html

SOURCE Neil Sahota

Originally posted here:
Artificial Intelligence Expert Neil Sahota Says AI Will Have Major Impact On 2020 Elections And In Medicine - Yahoo Finance

Read More...

GSK, Pfizer contradict on the future of consumer health JV report – Endpoints News

January 20th, 2020 5:49 am

SAN FRANCISCO Few CEOs tell a story better than bluebirds Nick Leschly.

He cuts a Jeff Bezos figure on stage at the Colonial Room, the JP Morgan presentation hall for A-list biotechs: lean and bald, fast-talking and vest-wearing. He explains in simple language, apologizing when he has to brush on the data. It helps that he has a good story to tell.

We treated them one time, Leschly tells a packed crowd, gesturing to the slide behind him. Look what happened.

The slide shows 9 horizontal bars studded with diamonds. Each bar, he explained, represented a sickle cell patient, and each diamond represented a severe medical event, such as a pain crisis. The diamonds stud one side before the therapy and vanish on the other, afterward.

A 99% reduction in these events this is a functional cure for sickle cell disease, Leschly says. This is unprecedented data.

Upstairs and an hour later, Ted Love stands before a narrow conference room in his suit and polka-dot tie. Love, the CEO of Global Blood Therapeutics, is a 60-year-old physician. His voice trails off at the end of sentences, and the story he tells is less compelling. There are no cured patients.

This is the first drug that addresses the root cause of sickle cell disease, Love says, speaking in front of a slide showing a white pill bottle for GBTs new drug Oxbryta. Right in the label, it says that this drug inhibits polymerization.

In the 60 years after scientists discovered the cause of sickle cell, almost no treatments emerged, even as the condition debilitated hundreds of thousands of Americans, most of them black or Hispanic. But the last few years have seen a resurgence of interest as new technologies have made the disease seem newly beatable.

Unlock this story instantly and join 70,000+ biopharma pros reading Endpoints daily and it's free.

SUBSCRIBE SIGN IN

See the original post here:
GSK, Pfizer contradict on the future of consumer health JV report - Endpoints News

Read More...

Ten Years of Unraveling the Genomics of Parkinson’s Disease – Technology Networks

January 20th, 2020 5:48 am

The International Parkinson Disease Genomics Consortium (IPDGC) has now been in existence for ten years. In an open accessarticlepublished in theJournal of Parkinson's Diseasethe consortium reviews the progress made over the past decade in the genomics of Parkinson's disease (PD) and related disorders including Lewy body diseases, progressive supranuclear palsy, and multiple system atrophy and looks ahead at its future direction and research priorities.

Since PD was first defined, it has been suspected that there was a genetic component. In June 2009, a small group of investigators met to discuss a potential research alliance focused on the genetics of PD. The outcome was the creation of the IPDGC, a group focused on collaborative genetics research, enabled by trust, sharing, and as little paperwork as possible. This article summarizes the efforts of the IPDGC to date and places these in the context of a decade of progress in PD genomics. It also discusses the future direction of IPDGC and its stated research priorities for the next decade.

The IPDGC was born out of a realization that no single investigator could deliver on the promise of modern human genetics in isolation, explained lead author Andrew Singleton, PhD, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA. We realized that to truly leverage the incredible gains in genetic technologies in the PD space, at scale, would require a highly collaborative approach. This notion brought a small group of PD geneticists together with the common goal of building an effective, transparent, and functional collaboration.

Since its inception, the IPDGC has grown considerably, now including more than 100 scientists from around the world with meetings at least once a year. The focus has also expanded to include clinical and functional investigation of PD at scale. Most recently, the IPDGC initiated major research efforts in East Asia and Africa and has prioritized collaborations with ongoing major efforts in India and South America.

The coordinated analysis of genome-wide association (GWA) data was perhaps the first success for IPDGC and has continued to be a mainstay of our work, noted Dr. Singleton. This work has centered on available genome-wide SNP genotyping of IPDGC members case and control cohorts from the USA, Canada, England, Wales, The Netherlands, France, Germany, Italy, Spain, Austria, Finland, Norway, Estonia, and Australia. These studies have involved collaboration within IPDGC and with groups from industry, including Genentech and 23andMe. The source diversity and size of these sample series have grown considerably, from the first efforts that centered on around 1,500 cases and a similar number of controls, to the most recent effort that included dense genotyping in more than 50,000 cases and proxy-cases, and around 1.4 million controls. As in other disorders, as sample size has grown, so has power and the number of loci detected. Currently, there are about 90 known risk variants for PD.

Collaboration among IPDGC members has furthered knowledge, including:

Future challenges the consortium has identified include expanding the known genetic architecture; genetics in diverse ancestries; advanced cohort building; and creating PD resources for the research community.

The importance of the dissection of genetic risk in non-European ancestry populations has led the consortium to invest more in establishing research in underrepresented groups. With the support of the Michael J. Fox Foundation for Parkinsons Research, the IPDGC has initiated largescale efforts in South East Asia and China and across Africa. It is also working closely with collections centered in India, LUX-GIANT, and LARGE-PD.

The field of PD genetics is one that has changed dramatically over the last ten years, commented Dr. Singleton. There has been an exponential growth in our appreciation of the genetic architecture of the disease and a greater understanding of how to proceed with genetic prosecution of PD.

Our future path promises to expand this work and leverage its clinical, mechanistic, and biological potential. Thus, while we believe the work of the IPDGC has had a significant and lasting impact on our field over the last ten years, we are even more excited by the course we have charted for the next decade.

Reference:The International Parkinson Disease Genomics Consortium (IPDGC). (2020).Ten Years of the International Parkinson Disease Genomics Consortium: Progress and Next Steps. The Journal of Parkinson's Disease.DOI: 10.3233/JPD-191854.

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

See original here:
Ten Years of Unraveling the Genomics of Parkinson's Disease - Technology Networks

Read More...

Cobb-Vantress appoints genetics executive – The Poultry Site

January 20th, 2020 5:48 am

Today, Cobb-Vantress appointed Dr Mark Cooper as managing director of genetics to oversee the companys global genetic program. Effective immediately, Dr Cooper will continue work to achieve genetic gains and competitive advantage through alignment of Cobbs breeding program with its product strategy, developing a portfolio of products to meet growing global market needs. He will report to Dr Aldo Rossi, vice president of research and development (R&D).

In his new role, Dr Cooper will lead a global, multifunctional team, including Dr Rachel Hawken, senior director of genetics; Dr Manouchehr Katanbaf, senior geneticist; and Dr Sriram Krishna, senior geneticist. Prior to this appointment, Dr Cooper previously worked as director of product testing. Since joining Cobb, he has also served as pedigree geneticist responsible for male line development, European director of genetics, director of genetics for all of Cobbs breeding programs, and director of product management.

Cobb has been dedicated to genetic research and the responsible use of technology for over 100 years, said Dr Rossi. Dr Cooper has made a big impact in his nearly 20 years with Cobb, and were looking forward to the continued advancements we expect him to accomplish in this new position.

In his time at Cobb, Dr Coopers research has focused on technology development and implementation in the breeding program, welfare parameters and meat quality. He has also spent time with global business leaders and customers to understand and update the R&D team on the product portfolio needed for the future. Most recently, he led Cobbs product testing team, helping to evaluate the companys product performance and development.

Im honored to take on the position of managing director of genetics, said Dr Cooper. Im fortunate because Cobb invests a significant percentage revenue into research and development, allowing us to continue leading the way in genetic progress.

Dr Cooper earned a bachelors degree in poultry science from Texas A&M University, a masters degree in poultry genetics from the University of Georgia, and a PhD in poultry genetics from the University of Arkansas.

See more here:
Cobb-Vantress appoints genetics executive - The Poultry Site

Read More...

Study Yields Insight Into Genetic Architecture of Anxiety – Psych Congress Network

January 20th, 2020 5:48 am

A genome-wide association study has identified several human genome regions related to anxiety risk. Researchers published their findings online in The American Journal of Psychiatry.

The findings are an important step forward in understanding anxiety disorders and the contribution of genes, said lead author Daniel F. Levey, PhD, of Yale University in New Haven, Connecticut, and the Veterans Affairs Connecticut Healthcare Center.

Dr. Levey and colleagues tapped data from the VA Million Veteran Program, a biobank that includes genetic, environmental, and medical information, to compare the genomes of almost 200,000 people.

The study identified 5 locations on the human genome associated with anxiety in Americans of European descent and 1 location in African Americans. Gene variants at the locations, researchers explained, could increase the risk for anxiety.h

Scans Show Shared Brain Abnormalities With Mood, Anxiety Disorders

The strongest locations were near genes involved with global regulation of gene expression (SATB1) and the estrogen receptor alpha (ESR1), according to the study. Another location (near MAD1L1) was previously linked with bipolar disorder and schizophrenia risk.

The study provides the first significant genome-wide findings regarding anxiety in people of African ancestry, Dr. Levey noted.

Minorities are underrepresented in genetic studies, and the diversity of the Million Veteran Program was essential for this part of the project, he said. The genetic variant we identified occurs only in individuals of African ancestry and would have been completely missed in less diverse cohorts.

Some 18% of participants in the Million Veteran Program are African American.

Jolynn Tumolo

References

Levey DF, Gelernter J, Polimanti R, et al. Reproducible genetic risk loci for anxiety: results from 200,000 participants in the Million Veteran Program. The American Journal of Psychiatry. 2020 January 7;[Epub ahead of print].

Million Veteran Program study sheds light on genetic basis of anxiety [press release]. Baltimore, Maryland: Veterans Affairs (VA) Research Communications; January 7, 2020.

Read more here:
Study Yields Insight Into Genetic Architecture of Anxiety - Psych Congress Network

Read More...

Florida Genetic Information Bill Advances in House – Government Technology

January 20th, 2020 5:48 am

(TNS) Incoming House Speaker Chris Sprowls had little trouble Thursday convincing members of a House health-care panel to approve legislation that would prohibit life-insurance, long-term care insurance and disability-insurance companies from using customers genetic information in changing, denying or canceling policies.

Florida would become the first state to have such a law if Sprowls proposal is ultimately passed by the Legislature and signed by Gov. Ron DeSantis.

Members of the House Health & Human Services Committee passed Sprowls bill (HB 1189) without any debate, and committee Chairman Ray Rodrigues, R-Estero, praised Sprowls for introducing the bill.

I think our privacy is important. And I think its equally important to be a visionary, to look forward and I 'm happy that Florida is going to be the state that leads the way on this issue, Rodrigues said.

Insurance industry lobbyists, who opposed the measure, sat quietly, agreeing to waive their speaking time.

Curt Leonard, regional vice president for state relations for the American Council of Life Insurers, said his association had expressed concerns on the issue for the past two years.

Weve expressed our concerns with Speaker Sprowls and other interested parties on this issue going back to 2018. So theres no point in repeating the same things over and over again, in the interest of the committee's time, Leonard said. That being said, we do share the speaker-designates (Sprowls) concerns about privacy. I think it's a concern for everybody.

The bill will have to clear the Commerce Committee before it would be ready to go to the full House. Sprowls, R-Palm Harbor, is slated to become speaker after the November elections.

In addition to preventing insurers from using the information in making policy decisions, Sprowls bill also would block the companies from requiring or soliciting genetic information from applicants.

Sprowls said insurance companies have for years been able to sell policies without having access to the genetic data.

Insurance carriers have been successful without access to genetic information. They have been able to provide affordable coverage to consumers without genetic information. Insurance is about spreading risk, not guaranteeing the outcomes or rewards to the (carriers). And affordable life, disability, and health insurance should not be available simply to the genetic elite, Sprowls said.

While Sprowls influence looms large in the House, he must convince the Florida Senate to go along. For that, Sprowls said he will look to Sen. Kelli Stargel, R-Lakeland, to spearhead the issue.

Senate President Bill Galvano, though, told The News Service of Florida that he supports a potential compromise on the issue.

Leonard said a compromise would authorize consumers to use their private information any way they want to. And that might include them wanting to share their genetic science or genetic testing information, he said. So we dont like the idea that consumers will be handcuffed in how they use that information.

2020 The Orlando Sentinel (Orlando, Fla.) Distributed by Tribune Content Agency, LLC.

Link:
Florida Genetic Information Bill Advances in House - Government Technology

Read More...

Functional validity, role, and implications of heavy alcohol consumption genetic loci – Science Advances

January 20th, 2020 5:48 am

Abstract

High alcohol consumption is a risk factor for morbidity and mortality, yet few genetic loci have been robustly associated with alcohol intake. Here, we use U.K. Biobank (n = 125,249) and GERA (n = 47,967) datasets to determine genetic factors associated with extreme population-level alcohol consumption and examine the functional validity of outcomes using model organisms and in silico techniques. We identified six loci attaining genome-wide significant association with alcohol consumption after meta-analysis and meeting our criteria for replication: ADH1B (lead SNP: rs1229984), KLB (rs13130794), BTF3P13 (rs144198753), GCKR (rs1260326), SLC39A8 (rs13107325), and DRD2 (rs11214609). A conserved role in phenotypic responses to alcohol was observed for all genetic targets available for investigation (ADH1B, GCKR, SLC39A8, and KLB) in Caenorhabditis elegans. Evidence of causal links to lung cancer, and shared genetic architecture with gout and hypertension was also found. These findings offer insight into genes, pathways, and relationships for disease risk associated with high alcohol consumption.

Alcohol consumption is associated with over 60 diseases, with the risk of these comorbidities generally increasing with greater exposure (1). Excessive consumption of alcohol is considered a result of complex interactions between genetic and nongenetic risk factors. Nongenetic factors associated with levels of alcohol intake include gender (2), age at first alcohol use (3), duration of poverty and involuntary unemployment (4), and other lifestyle risk factors (5).

Meta-analysis from twin and adoption studies has shown that half of the variance for alcohol use disorder (AUD) is explained by genetic factors (6). The discovery of well-replicated risk loci, however, has been limited to the alcohol metabolizing genes alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH). Missense variants, rs1229984 (G-->A; p.Arg48His) in ADH1B and rs671 (G-->A; p.Glu504Lys) in ALDH2, are protective against higher alcohol consumption and alcohol misuse phenotypes (7). For example, in a meta-analysis of ~3800 European ancestry individuals, the ADH1B rs1229984 variant was strongly associated with reduced risk of alcohol dependence and lower number of maximum drinks in 24 hours (8). The ADH1B and other ADH and ALDH variants that are associated with alcohol consumption occur at low frequency among European ancestry populations but are more common in East Asian ancestry populations, where the standardized population prevalence of alcohol misuse is lower (9).

Larger samples and genome-wide screens have been used to identify previously unidentified loci beyond the ADH-ADLH cluster. Alcohol consumption phenotypes are of specific interest to the field as they are often more applicable to the wider population than the AUD criteria. Through genome-wide association studies (GWAS), single-nucleotide polymorphisms (SNPs) mapping to/near KLB, AUTS2, SERPINC1, ANKRD36, GCKR, PXDN, CADM2, HGFAC, SLC39A8, and TNFRSF11A have been associated with alcohol consumption in European ancestry populations at genome-wide significance (P < 5 108) (1015). However, apart from association signals at KLB and GCKR, strong evidence of replication has been limited.

In this study, our aim was to determine factors associated with heavy alcohol consumption in white British individuals from the U.K. Biobank (UKB) (www.ukbiobank.ac.uk/), alongside exploring the functional relevance of genome-wide significant variants using model organisms and data mining techniques.

The application of the phenotype definition resulted in the identification of 21,967 cases and 103,282 controls that had complete data for all covariates. The covariates included in the final logistic regression model and carried forward to the GWAS analysis were (table S1) age at recruitment, sex, smoking status (anytime versus never), property ownership (own versus rent), body mass index (BMI), Townsend deprivation index at recruitment, adopted as a child, and long-standing illness, disability, or infirmity (yes or no).

We tested for SNP-level association with our high alcohol consumption phenotype in UKB. A total of 11,141,077 SNPs survived central quality control (QC) by UKB and post-GWAS filtering for imputation quality and minor allele frequency. The GWAS data test statistics showed modest deviation from the null (GC = 1.09; Fig. 1, inset), although linkage disequilibrium (LD) score regression intercept = 1.02 suggests most of the inflation is consistent with polygenic architecture. We then carried forward lead SNPs at P < 5 106 from UKB to Genetic Epidemiology Research in Adult Health and Aging (GERA) for replication. We report validated associations that meet genome-wide significance in the meta-analysis of UKB and GERA, which also demonstrate nominal association with the same direction of effect in GERA (Table 1). A summary of all SNPs reaching P < 5 108 in UKB can be found in table S2. We identified six loci attaining genome-wide significant association with alcohol consumption after meta-analysis and meeting our criteria for replication: ADH1B (rs1229984; P_meta = 2.3 1066); KLB (rs13130794; P_meta = 5.7 1016); BTF3P13 (rs144198753; P_meta = 4.1 1029); GCKR (rs1260326; P_meta = 1.5 1013); SLC39A8 (rs13107325; P_meta = 6.7 109); and DRD2 (rs11214609; P_meta = 4.3 109) (Table 1).

Inset: QQ plot of expected versus observed GWAS results from UKB, demonstrating modest deviation from the null, GC = 1.09.

OR, odds ratio; CI, confidence interval.

Multiple distinct signals of association observed at alcohol consumption loci. Conditional analyses revealed an additional signal (P < 1 105) (Table 2) at the SLC39A8 locus (NFKB1). Given ADH1B and BTF3P13 are located <1 Mb apart on q23 of chromosome 4, we conducted a wider conditional analysis across a 1.5-Mb region, which included both SNPs. The analysis identified eight independent SNPs mapping to/near ADH1A, ADH1B, ADH4, ADH5, TSPAN5, and EIF4E. The signal mapping to BTF3P13 did not meet locus-wide significance in conditional analysis, suggesting a false positive for this variant.

Joint models refer to the estimated joint effects of all selected SNPs in a region (i.e., all independent SNPs are fitted together).

Previously reported loci. The signals described in this section meet our validated association criteria and have been reported for various alcohol phenotypes by other groups. The lead SNP at ADH1B, rs1229984 [risk allele frequency (RAF), 0.980; P = 3.3 1036; fig. S1A], is the missense variant (G-->A; p.His48Arg) that has been widely replicated. The lead SNP rs13130794 (RAF, 0.632; P = 4.0 109; fig. S1B) is located in the KLB locus and has been reported to be associated with alcohol intake in the UKB (11) and a separate European cohort of >98,000 individuals (10). The lead variant in chromosome 2, rs1260326 (RAF, 0.612; P = 2.6 108; fig. S1C), is in GCKR, a glucokinase regulatory gene. This specific SNP has been reported as genome-wide significant for alcohol consumption (i.e., drinks/week) in large-scale European ancestry (11, 13) and transethnic populations (15). The lead SNP rs13107325 (RAF, 0.928; P = 1.6 108; fig. S1D) is in the zinc transporter gene, SLC39A8, which has been linked in Europeans to AUD Identification Test (AUDIT) (14) and AUDIT-C outcomes, and to AUD diagnosis (15). Last, rs11214609 (RAF, 0.395; P = 4.3 109; fig. S1E) was the SNP in the DRD2 locus. DRD2 often has been cited in addiction phenotypes and has been identified for AUD, but not alcohol consumption (15).

Nonreplicated signals reported elsewhere. We also observed genome-wide significant evidence of association in UKB at FTO and CRHR1, but these signals could not be validated in GERA. There is, however, evidence for association with alcohol-related phenotypes at these loci from other studies. The lead SNP rs55872725 (RAF, 0.599; P = 2.6 108) is in the FTO gene. This locus has recently been reported to be associated with AUDIT-C and AUD diagnosis in European ancestry individuals (15). Different index variants were reported between studies, rs62033408 for AUDIT-C and AUD diagnosis outcomes, but the SNPs are in strong LD with each other (r2 = 0.92). The FTO locus has been strongly associated with BMI, obesity, and, subsequently, type 2 diabetes as a clinical end point. Our lead SNP in this locus is in complete LD (r2 = 1.0) with rs1558902 in Europeans, which is the lead SNP for BMI in the largest published GWAS to date (16). The CRHR1 locus, with rs1635291 (RAF, 0.754; P = 4.5 1010) as the lead SNP, has been identified through gene-based analysis in a previous alcohol consumption GWAS where never drinkers were excluded. However, no other groups have reported this locus directly through GWAS. Given the previous associations for these loci with covariates included in our analysis but not in the GERA dataset, we explored the potential for collider bias at rs55872725 when not adjusting for BMI, and rs1635291 when not adjusting for smoking; the results were consistent at 6.5 106 and 2.8 108, respectively. We also found our lead SNP in the CRHR1 locus to be in strong LD (r2 = 0.87) with a tag SNP rs1800547 for a common inversion polymorphism in 17q21.31 (17).

Of the six validated variants from the UKB and GERA cohorts, three were identified as expression quantitative trait loci (eQTLs) through the Genotype-Tissue Expression (GTEx) database (table S3). rs11214609 showed evidence of being an eQTL in various tissues for nearby genes, ANNK1 and TTC12. rs13130794 was associated with the expression of RFC1 in the cerebellar hemisphere and skeletal muscle and UDGH in blood. rs1260326 was a broader eQTL with evidence across eight loci and various tissues including skeletal muscle, thyroid, and adrenal glands. Table S4 describes the LD between the top eQTL SNP for any eQTL signal and the GWAS SNP. None of the SNP pairs demonstrated evidence of colocalization based on a threshold of LD r2 > 0.8.

The validated SNPs were submitted to Gene ATLAS to explore phenome-wide association study (PheWAS) outcomes in disease phenotypes via International Statistical Classification of Diseases, 10th Revision (ICD-10) codes. Evidence suggests that these SNPs contribute to a range of diseases including alcohol dependence, hypertension, skeletal disorders, gout, alcoholic liver disease, ischemic heart diseases, metabolic disorder, obesity, and diabetes mellitus (table S5). The ADH1B variant is associated with lipid metabolism disorder, giving further link between alcohol intake and liver fat accumulation.

A set of 37 loci, which reached 5 106 with heavy drinker status phenotype in UKB, were submitted to the Reactome Knowledgebase for pathway analysis (table S6). Six pathways across three distinct processes were found to be significant. The most prominent outcome related to signaling of phosphatidylinositol 3-kinase (PI3K) and PI3K/AKT pathways, particularly in reference to cancer. Dysfunction of the PI3K/AKT pathway is widely implicated in many cancers and is a key regulator of cell survival through downstream targets (18). The genes implicated in these pathways were KLB and ESR1 (fig. S2). The other two pathways were neurexins and neuroligins, driven by LRRTM4 and NRXN3, and TFAP2 (AP-2) family regulation of transcription of growth factors and their receptors, driven by ESR1.

Through genetic correlation analysis of the entire genome, we identified 21 significant correlations that survived multiple testing correction. These outcomes are summarized in Fig. 2. The traits with the strongest correlations included smoking variables [e.g., ever versus never smoked (rg = 0.48, PFDR = 2.60 1013) and age of smoking initiation (rg = 0.41, PFDR = 0.006)], several lung cancer outcomes [e.g., squamous cell lung cancer (rg = 0.37, PFDR = 0.006) and lung cancer (rg = 0.36, PFDR = 1.20 104)], and mothers age at death (rg = 0.41, PFDR = 1.60 104). Several education measures and mental health conditions were also found to have significant correlations.

Mendelian randomization (MR) was used to examine the causal relationship between our heavy drinker case-control phenotype and 111 selected traits and clinical outcomes. The number of SNPs used for instrumental variables for each outcome test varied between two and six. Twelve outcomes including four insulin-related and two lung cancer outcomes demonstrated nominal significance using the inverse varianceweighted (IVW) method, although only evidence of a protective effect for ischemic stroke survived multiple testing correction (table S7). The MR-Egger regression intercept demonstrated no evidence of horizontal pleiotropy for the 12 outcomes (P 0.11). Single SNP analysis revealed that rs1229984 was not included in the instrumental variable for ischemic heart disease (SNP or appropriate proxy not available in the outcome dataset). Given rs1229984 demonstrates a consistent and large effect size across genetic studies of alcohol-related phenotypes, it is questionable whether the outcome can be considered as truly representative for this disease.

To further explore the potential causal effect of heavy alcohol consumption on lung cancer outcomes and allow for potential pleiotropy that might be driven by smoking, we repeated our GWAS analysis stratified for smoking status (ever versus never) and performed MR to assess potential collider bias. The SNPs used as the instrumental variable in the original analysis were retained, and lung adenocarcinoma and lung cancer were the only outcomes investigated. Evidence of consistent outcomes was observed in both stratified groups using IVW, although lung cancer in never smokers was the only outcome that did not reach the statistical significance threshold (P = 0.085).

To verify whether validated genetic targets (i.e., ADH1B, GCKR, SLC39A8, and KLB) had a conserved role in phenotypic responses to alcohol, we investigated the acute effects of ethanol on the nematode worm, Caenorhabditis elegans. In comparison to wild-type animals, those with a loss-of-function mutation in the worm ortholog for ADH (sodh-1 in C .elegans) had a statistically enhanced ethanol response (Fig. 3) as has been previously described in detail (19). The effect of intoxicating ethanol on coordinated locomotion was next quantified for loss-of-function mutations in C. elegans glucokinase (GK; hxk-1) and solute carrier family 39 member 8 (SLC39A8; zipt-15) (Fig. 3). Without an ortholog for GCKR in C. elegans, we instead analyzed its downstream effector protein glucokinase itself. Loss-of-function mutations in these genes significantly reduced the effect of ethanol for GK and SLC39A8 (Fig. 3), underlining a conserved role for these genes in whole-animal responses to alcohol. We also quantified single mutations in the C. elegans orthologs for the -Klotho protein (KLB; klo-1 and klo-2) and found that individual mutations did not alter the ethanol phenotype (fig. S3A). A compound mutation of both klo-1 and klo-2 (20), however, did have a significantly enhanced ethanol effect (Fig. 3).

C. elegans with loss-of-function mutations in worm orthologs to ADH (sodh-1), glucokinase (hxk-1), solute carrier family 39 member 8 (zipt-15), and -Klotho protein (klo-2;klo-1) were exposed to ethanol, and the resultant effect on locomotion rate was determined. Results are presented normalized to locomotion of untreated worms [basal locomotion rate: 99.03 1.47 (Bristol N2 controls), 103.13 3.66 (sodh-1), 87.37 1.91 (hxk-1), 31.43 2.97 (zipt-15), and 99.90 21.7 (klo-2;klo-1)]. *P < 0.05.

To validate the effects seen in individual mutant strains, we performed RNA interference (RNAi) experiments to knock down expression of the contraindicated genes. In comparison to control, RNAi knockdown of GK (hxk-1) and SLC39A8 (zipt-15) resulted in the same phenotypic effects as did the mutations (Fig. 4). In our RNAi experiments, knockdown of ADH (sodh-1) did not result in a significant decrease. Similar to the KLB mutations, individual knockdown of C. elegans KLB (klo-1 or klo-2) did not statistically enhance the ethanol phenotype and neither did knocking down both klo-1 and klo-2 simultaneously (Fig. 4). The lack of effect in the double knockdown is perhaps expected given that RNAi efficiency can be reduced with multiple targets (21). To validate the alcohol effect of KLB in C. elegans in an alternative method, we performed RNAi on individual KLB genes in the mutant strain of the other ortholog (i.e., klo-1 RNAi in the klo-2 background; klo-2 RNAi in the klo-1 background). In both cases, there were exceptionally enhanced effects of ethanol similar to that seen with the compound mutant strain (fig. S3B).

RNAi knockdown of worm orthologs to glucokinase (hxk-1) and solute carrier family 39 member 8 (zipt-15) phenocopies the loss-of-function mutations. Results are presented as locomotion of worms treated with ethanol normalized to untreated worms [basal locomotion rate: 87.63 21.6 (empty vector control), 94.17 2.91 (sodh-1), 77.60 2.34 (hxk-1), 60.0 2.34 (zipt-15), 90.97 3.56 (klo-1), 99.13 2.78 (klo-2), and 110.0 3.40 (klo-2;klo-1)]. *P < 0.05; n.s., not significant.

We report here a large alcohol consumption GWAS, including 125,249 white British participants, with subsequent replication and meta-analysis in an additional 47,967 individuals. Moreover, and as promoted by Salvatore and colleagues in this field (22), we conducted a post-GWAS study to investigate the biological implications of our findings. This includes providing evidence of a conserved role in phenotypic responses to alcohol for all targets available for investigation (ADH1B, GCKR, SLC39A8, and KLB) in C. elegans.

The primary strengths of this study are the (i) large sample size; (ii) replication and subsequent meta-analysis; (iii) post-GWAS analysis, including functional assessment using C. elegans; and (iv) use of a mixed-model approach in GWAS to account for relatedness. There are, however, several limitations that require discussion. First, the alcohol data and, therefore, the case-control phenotypes are based on self-reported alcohol intake. It is well documented that individuals underreport their alcohol consumption for a number of reasons. This presents risk of cases being mislabeled as controls, alongside the granularity of the data being reduced by the categorical approach. There are also differences in the measurement scale between discovery and replication cohorts. This difference was handled by applying a z score approach to meta-analysis. Second, we restricted analysis to those of white British ancestry to limit population structure variability on outcomes. This restricts generalizability outside of European populations. Third, we recognize limitations to our MR approach: (i) MR is considered most powerful when instrumental variables are from a continuous trait. This is of greater concern, however, when a disease-specific phenotype is used for instrument selection because of the likely contribution of various factors in disease pathology; and (ii) an inherent assumption of MR is that variants show no pleiotropy or direct effects on the outcome. This requires knowledge of the underlying biology under investigation, although this is rarely complete. Last, we were unable to undertake functional assessment of all genome-wide significant loci due to there being either no specific C. elegans orthologs, or too many nonspecific orthologs, or fatal consequences of gene knockdown.

The largest and most robust effects were observed in ADH1B, including replicated findings from the work in C. elegans for ADH (19), providing confidence for the selected phenotype. The biological validity of polymorphisms in ADH loci is well documented and discussed in detail in other GWAS publications (12).

KLB has been previously associated with alcohol phenotypes in European populations (10, 12). A biological basis for KLB has been proposed in mice, where those lacking -Klotho had increased alcohol consumption (10). This behavior was refractory to recombinant fibroblast growth factor 21 (FGF21), a hormone involved in sugar intake regulation and for which -Klotho is an obligate coreceptor. Hence, down-regulation of KLB may lead to sustained intake of alcohol and/or high-sugar food. Moreover, loss of both KLB isoforms in C. elegans caused an enhancement in the ethanol effects. Further evidence for energy processing pathways being implicated in alcohol consumption is demonstrated by the genome-wide significant outcomes for GCKR and SLC39A8, with these findings being consistent with recent publications (11, 13, 14). The data from our functional work in hexokinase and ZRT/IRT-like protein transporter supports the role of glucose metabolism pathways in the susceptibility to heavy alcohol consumption by demonstrating attenuation of the depressive effects of high-dose alcohol when hxk-1 and zipt-15 are independently knocked down. Although we failed to demonstrate replication between the UKB and GERA cohorts, potentially due to variation in phenotype, evidence from other GWAS showed consistent effects for FTO (23). The suggestive association with this pleiotropic locus adds further plausibility of common pathways implicated in the consumption of food and alcohol. The purported shared pathogenic architecture may result in dysregulation of brain reward pathways leading to excess consumption (24). Controlling for BMI within our GWAS suggests that the associations for alcohol consumption are independent of BMI, adding weight to the hypothesis of a potentially shared, rather than mediated, pathways.

DRD2 encodes the dopamine receptor 2 subtype and is linked to several neurobiological processes, including functional activation of reward circuits (25). Data from in vivo and in vitro experiments show DRD2 to be a susceptibility gene for alcohol dependence (26), and altering DRD2 expression leads to differential responses to substances and stimuli (27), conferring increased risk for addiction. Moreover, evidence suggests increased risk of relapse in alcohol and cocaine dependence, and heightened heroin, nicotine, and glucose craving when polymorphisms of DRD2 are present or there is low D2 receptor availability (28). The association of DRD2 with alcohol was confirmed in GWAS findings for AUD but not alcohol consumption, with authors proposing that the central nervous system is a fundamental element in the progression to clinical diagnosis (15). Our findings are somewhat contradictory given that participant categorization is based on U.K. alcohol units consumed per week, although the quantities for cases are often associated with high risk of AUD.

Together, the loci outside of the ADH/ALDH cluster suggest several common pathways associated with different types of compulsive behavior and addiction phenotypes. Considerable evidence from animal models and from humans supports convergence of these common etiologies in the brains limbic system regardless of the prior distinct mechanism of action and ultimate observable phenotype (29, 30). This suggests that addiction might be better considered as a pathobiological risk with different endotypes, rather than each specific phenotype (e.g., alcohol dependence, drug addiction, and gambling addiction) being independently characterized. From a therapeutics perspective, these outcomes provide additional and supportive evidence toward a number of targets that might be amendable to pharmacological intervention. Further investigation is required to determine which sites have the greatest potential. Data from the Open Targets resource (www.opentargets.org/) suggest that 49 drugs have reached phase IV investigation for DRD2 across a range of indications, including mental health disorders and cocaine dependence; no drugs are in development for ADH1B, KLB, GCKR, or SLC39A8. FGF21 has been explored due to links with KLB, but no drugs are in the market yet.

Using the GWAS outcomes from UKB enabled us to examine the relations between key variants/loci and traits and disease phenotypes. Genetic correlation analysis and MR consistently demonstrated an association with lung cancer. Determining alcohols contribution to lung cancer often has been limited by the strong positive correlation between alcohol intake and smoking. However, the outcomes from the MR provide potential evidence of a causal relationship in our overall sample and when stratified by smoking status. Alcohol is a known carcinogen and is implicated in cancers of the liver, colon, rectum, head and neck, and breast, for example (31), while evidence for lung is variable (32, 33). Lung cancer is a complex and multifactorial disease involving genetic and a range of measurable and nonmeasurable environmental and lifestyle factors. Hence, heavy alcohol consumption is one potentially modifiable risk factor to reduce disease incidence. An alternative hypothesis is through a joint risk locus in KLB that independently drives alcohol consumption and cancer risk. In addition to the above, -Klotho inhibits PI3K and, subsequently, AKT, an important pathway in normal cell function. The dysfunction of the PI3K/AKT pathway, identified in our pathway analysis, has been cited in cancerous cells and as a risk factor in cancer onset (18, 34). Down-regulation of KLB has been reported across several cancers (35, 36). However, some variations in findings exist (37), and no evidence is available in lung cancer. Basic cell line study would provide initial data on -Klotho expression in lung tumor cells.

Links to other diseases were also found. Drinking heavily was suggested as a protective factor for ischemic stroke. This is not consistent with traditional epidemiological findings or other MR findings using rs1229984 as the instrumental variable (38). However, the lack of rs1229984 in our instrumental variable for this analysis means the outcome should be interpreted with caution. The nominal evidence in several insulin measures suggests a wider biological association with glucose regulation, linking back to the potential importance of energy metabolism pathways in alcohol consumption. ADH1B and GCKR were associated with gout, and ADH1B alone with hypertension. The lead SNP at GCKR, rs1260326, has been shown to be a risk variant for gout in a separate GWAS (39), and rs1229984 in ADH1B has been identified for systolic blood pressure using a functional enrichment approach. Increasing alcohol consumption is a known risk factor for both gout and hypertension (40). Last, there was evidence for several skeletal complications with identified alcohol consumption variants. Alcohol intake represents a dose-dependent risk factor for fragility fractures due to the direct effects of alcohol on bone cell metabolism. Chronic alcohol consumption has been associated with a twofold increased risk of hip fracture in prospective cohort studies involving more than 16,000 subjects (41).

Our findings offer insight into genes, pathways, and causal relationships for disease risk associated with heavy alcohol consumption. The inclusion of model organism work to investigate the conserved role of loci alongside GWAS outcomes is novel in the alcohol field and adds validity for relevant outcomes. In addition, the correlation between the C. elegans phenotypic data with genome-wide association in humans reinforces a link between the acute physiological effect of alcohol and predisposition to excessive alcohol consumption. Specific findings suggesting joint reward/addiction pathways, the role of energy metabolism, casual links to lung cancer, and shared genetic architecture with gout and hypertension are of particular interest. Further investigation is required, however, to realize the potential of these outcomes and result in meaningful populationor clinical-level impact.

UKB is a large population cohort of ~502,000 individuals from the United Kingdom aged 40 to 69 years at the time of recruitment. Baseline assessment was undertaken at one of 22 centers across the United Kingdom between 2006 and 2010. Each participant completed a comprehensive demographic, lifestyle, and health questionnaire, underwent clinical phenotyping, provided biological samples (i.e., blood, urine, and saliva), and agreed to have his or her health record accessed for baseline and follow-up outcomes (42). Ethical approval for UKB was gained from the Research Ethics Service (REC reference: 16/NW/0274), and written informed consent was obtained from all participants. The current analyses were conducted under approved UKB data application number 15110.

Phenotype definition. Questions from the UKB baseline assessment were used to develop two study groups: heavy drinkers (cases) and drinkers not reaching criteria for cases (controls). All participants who indicated they consumed alcohol were asked to quantify their intake per week or per month using standard drink sizes [e.g., In an average WEEK, how many glasses of RED wine would you drink? (there are six glasses in an average bottle)]; pictures accompanied these questions to provide visual representation of each measure. We then applied a standardized number of U.K. alcohol units to each drink to enable an estimated number of units per week to be calculated (see the Supplementary Materials for more detail). Sex-specific heavy drinking was then defined as >35 U/week for women and >50 U/week for men. Any cases with values >4 SDs above the gender-specific means were removed. Controls were individuals who were not current abstainers from alcohol (i.e., 1 U/week) but did not reach the sex-specific criteria for heavy drinking and were drinking at similar levels to 10 years previous.

Genotyping, imputation, QC, and GWAS. In July 2017, UKB released genetic information (directly typed and imputed genotypes) for the entire cohort (n = 487,406) to approved collaborators. Most (90%) of the participants were genotyped on the UKB Axiom Array, with the remaining 10% genotyped on the Affymetrix UK BiLEVE Axiom Array. There is >95% content overlap between arrays. Genotyping, QC, and imputation were performed centrally by UKB and has been previously described (43). Imputation was performed up to combined reference panels from the 1000 Genomes Project (Phase 3), UK10K, and Haplotype Reference Consortium (44). Analyses were restricted to a subset of white British individuals, defined on the basis of self-reported ethnicity and genetic data.

Using UKB data, univariate and multivariate logistic regressions were used to determine covariates to be included in the GWAS analysis. Variables only available for the entire cohort and implicated in previous research were considered, and any values >4 SDs from the mean were removed (n = 7649 participants removed due to missing data). Variables reaching P < 0.01 in separate univariate analysis were carried forward to a multivariate model, where the stepAIC function of the MASS R package was used to determine stepwise entry of variables into the model. Collinearity was determined using variance inflation factor, and variables were accordingly removed from the final model (Variance Inflation Factor >10). An a priori decision was made to include age and sex in all models. Our rationale for using this approach is twofold: first, to account for confounding factors that may bias effect estimates, and second, to improve power by reducing residual variance.

Genetic association analysis in autosomes was conducted using a linear mixed model in BOLT-LMM v2.3.1 (45), adjusted for age at recruitment, sex, genotyping array, and nongenetic covariates identified in the logistic regression model. The BOLT-LMM model includes a random effect derived from a genetic relationship matrix to account for population structure and relatedness. Potential P value inflation due to residual population structure and relatedness was checked using genomic control following filtering of variants based on imputation quality (INFO 0.4) and minor allele frequency of 0.005. Distance-based clustering was used for defining loci, such that genome-wide significant SNPs were ranked from most significant to least significant, and SNPs were retained if they did not map 500 kb of a more significant SNP. Variants reaching P < 5 106 and surviving distance-based clustering (i.e., lead SNPs) in the UKB cohort were explored in the GERA cohort for the purposes of replication.

The GERA cohort was used for replication. GERA is part of the Kaiser Permanente Research Program on Genes, Environment, and Health (RPGEH) and has been described in detail elsewhere (46). In short, the cohort comprises 110,266 adult men and women who are consented participants in the RPGEH, an unselected cohort of adult participants who are members of Kaiser Permanente Northern California, an integrated health care delivery system. All study procedures were approved by the Institutional Review Board of the Kaiser Foundation Research Institute.

For this replication analysis, 47,967 GERA participants of non-Hispanic white ethnicity who had alcohol consumption information were included. Alcoholic drinks consumed per week as a quantitative trait (drinks/week) was assessed on the basis of the RPGEH survey as previously described (12) and as part of the Supplementary Materials. Genotyping using Affymetrix Axiom arrays (Affymetrix, Santa Clara, CA, USA) (47, 48), imputation using the cosmopolitan 1000 Genomes Project reference panel, and GWAS analysis were undertaken as detailed in the Supplementary Materials.

METAL was used to perform a fixed-effects meta-analysis between the UKB and GERA cohorts using Stouffers method to account for the effect sizes in discovery and replication being on different scales (49). An overall z-statistic and P value were calculated from a weighted sum of the individual statistics. Weights are proportional to the square root of the number of individuals examined in each sample and selected such that the squared weights sum to 1.0.

A validated association was defined as follows: (i) reaching P < 5 106 in the discovery cohort, (ii) demonstrating nominal association with the same direction of effect in the replication cohort, and (iii) meeting genome-wide significance in the meta-analysis of both datasets sets.

Conditional analysis was performed on validated associations using Genome-wide Complex Trait Analysis (50) (http://cnsgenomics.com/software/gcta/) and the GWAS outcomes from the UKB to identify independent signals in the same region as each lead SNP (500 kb); one model was fitted per region. A set of 5000 randomly selected UKB white British participants was used to develop a reference set to approximate LD. A threshold of P < 1 105 was used to select index SNPs for independent signals in each region, where the conditional estimates were derived from fitting all independent SNPs jointly (i.e., joint model).

Expression quantitative trait loci. The GTEx Portal (http://www.gtexportal.org) was used to assess whether the lead SNP at each locus was an eQTL for local genes across the range of available tissues (51). This approach uses gene expression information across various human tissue types and genotype data to build information on eQTLs using a 1-Mb cis-window around the transcription start site. All tissue types with more than 70 samples available within GTEx were evaluated in our analysis including the brain, heart, liver, skeletal muscle, and skin. Significant eQTLs were based on a false discovery rate (FDR < 0.05) correction. The LD between the top eQTL SNP for any eQTL signal and the GWAS SNP was assessed to explore whether the two signals colocalize with each other; an LD r2 > 0.8 in Europeans from the 1000 Genomes was considered evidence of colocalization.

Genetic correlations. LD Hub v1.9.0 (http://ldsc.broadinstitute.org/ldhub/) was used to identify genetic correlations through LD score regression between the binary alcohol phenotype and other complex traits (52). This method uses individual SNP allele effect sizes from GWAS summary statistics and the average LD in a region to estimate bivariate genetic correlations. We tested for genetic overlap between alcohol consumption from our GWAS and disease outcomes and related traits in European cohorts available in the LD Hub, except for UKB outcomes and metabolites due to the large number of potential comparisons. FDR < 0.05 was used to account for multiple comparisons.

Mendelian randomization. MR-Base v0.4.21 was used for performing two-sample MR to explore the causal relationship between alcohol consumption and other disease outcomes and related traits (53). Outcomes were selected from the NHGRI-EBI GWAS catalog and filtered for European ancestryonly populations. All genome-wide significant SNPs were initially considered. Before MR analysis, the identified SNPs were explored for independence using estimated LD scores from the 1000 Genomes Project European sample, where r2 0.001 among SNPs in a 10,000-kb region resulted in only the SNP with the lowest P value being retained. One hundred eleven outcomes were selected on the basis of being diseases of interest, metabolites influenced by alcohol and prominent in subsequent alcohol-related disease onset or progression (e.g., triglycerides), or other consequences of heavy alcohol consumption. Harmonization between exposure data and outcome data was undertaken to ensure effects corresponded to the same allele. Causal estimates between exposure and outcomes were obtained using the two-sample MR IVW method with FDR for multiple comparisons. Sensitivity analyses to account for pleiotropy were performed using MR-Egger regression and weighted median approaches. The weighted median test has been suggested as an alternative to the MR-Egger when the instrumental variable contains a small number of SNPs.

PheWAS. Gene ATLAS (http://geneatlas.roslin.ed.ac.uk/) was used as a lookup for outcomes from PheWAS analysis performed on UKB traits (54). The database contains data from >450,000 white British individuals, >31 million variants, and 778 traits; only ICD-10 traits were considered (n = 496). This information was used to derive a phenome-wide significance threshold, divided by the number of independent tests, i.e., 1.68 105 [0.05/(496*6)].

Pathway analysis. Reactome pathway knowledgebase (https://reactome.org/) was used to undertake pathway analysis (55). The Reactome Knowledgebase systematically links human proteins to their molecular functions, providing a resource that operates both as an archive of biological processes and as a tool for discovering unexpected functional relationships. Loci identified through distance-based clustering at a relaxed threshold of P < 5 106 from the GWAS analysis were included. These loci were mapped to pathways, and a P value was calculated on the basis of the overlap between the query and the pathway expression; an FDR correction was applied by the software.

C. elegans is an excellent genetic model for investigating whole-animal effects of alcohol (5658). Similar to humans, acute exposure to intoxicating alcohol induces a dose-dependent reduction in coordinated movement of C. elegans both in solution (59) and on solid agar (60). Strains of C. elegans were selected on the basis of the outcomes from the present GWAS at the level of P < 5 108 and having evidence of replication in GERA or being reported as genome-wide significant in other alcohol phenotype studies.

Phenotypic and RNA interference experiments were performed at 20C in a temperature-controlled room on young adult hermaphrodites selected from sparsely populated NGM (nematode growth media) plates. As we and others have previously demonstrated (59, 60), exposure to 400 mM external ethanol reduces coordinated locomotion of wild-type (Bristol N2) animals by ~70%. An external concentration of 400 mM ethanol is equivalent to an internal concentration of ~20 to 70 mM, which is equivalent to a blood alcohol level of ~0.1 to 0.4% and is consistent with levels of intoxication experienced by humans. Locomotion rate was the outcome of interest and was quantified by thrashing in Dents solution [140 mM NaCl, 6 mM KCl, 1 mM CaCl2, 1 mM MgCl2, and 5 mM Hepes (pH 7.4) with bovine serum albumin at 0.1 mg/ml] as previous described (59, 60). See the Supplementary Materials for full details.

All functional data are expressed as means SE. Thirty treated and untreated animals were analyzed and compared per strain per experiment. Statistical significance was assessed by one-way analysis of variance (ANOVA) with post hoc Bonferroni correction for multiple comparisons.

Supplementary material for this article is available at http://advances.sciencemag.org/cgi/content/full/6/3/eaay5034/DC1

Supplementary Methods

Table S1. Summary of final multivariable logistic regression model.

Table S2. Summary of genome-wide significant SNPs following distance-based clumping on the UKB cohort, and the replication cohort and meta-analysis outcomes.

Table S3. eQTL analysis outcomes.

Table S4. LD between the top eQTL SNP for any eQTL signal and the GWAS SNP.

Table S5. Variant-trait significant outcomes from PheWAS.

Table S6. Variants at 5 106 and submitted to the Reactome Knowledgebase.

Table S7. Mendelian randomization results for nominally significant outcomes in the IVW analysis and FDR outcomes using the IVW method.

Fig. S1. LocusZoom plots for lead SNPs from GWAS on alcohol phenotype in the entire cohort.

Fig. S2. Constitutive signaling by aberrant PI3K in cancer.

Fig. S3. Individual C. elegans b-Klotho genes outcomes.

References (6171)

This is an open-access article distributed under the terms of the Creative Commons Attribution license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

H. Kranzler, H. Zhou, R. Kember, R. V. Smith, A. Justice, S. Damrauer, P. S. Tsao, D. Klarin, D. J. Rader, Z. Cheng, J. P. Tate, W. C. Becker, J. Concato, K. Xu, R. Polimanti, H. Zhao, J. Gelernter, Genome-wide Association Study of Alcohol Consumption and Use Disorder in Multiple Populations (N = 274,424). bioRxiv 527929v1 [Preprint] (2019).

Acknowledgments: Funding: This work was supported by the Medical Research Council (grant number MR/S000607/1). Genotyping of the GERA cohort was funded by a grant from the National Institute on Aging, National Institute of Mental Health, and National Institute of Health Common Fund (RC2 AG036607). Analysis of GERA data was supported by NIH grants National Eye Institute grants R01 EY027004, R01 DK116738, and R21 AA021223 (E.J.). Author contributions: A.T., A.P.M., and M.P. conceived the project. A.T., J.C., and A.P.M. performed the discovery, replication, and in silico analysis. E.J., H.C., and J.Y. provided access to the replication cohort and data analysis. J.B. and T.K. provided access to C. elegans assays and performed the experiments. A.T., J.C., and J.B. produced data visualization. A.P.M. and M.P. supervised the project. A.T. wrote the original draft. All authors critically reviewed the drafts of the manuscript and approved the final version. Competing interests: The authors declare that they have no competing interests Data and materials availability: All data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials. The data from UKB were provided under license by UKB, who is the owner of the data. Requests for access to the data should be directed to UKB as per the material transfer agreement. Additional data related to this paper may be requested from the authors.

Read more from the original source:
Functional validity, role, and implications of heavy alcohol consumption genetic loci - Science Advances

Read More...

Healthy Headlines: Four common myths about genetic testing and why they are not accurate – User-generated content

January 20th, 2020 5:48 am

St. Elizabeth Healthcare

If you could take a simple test that would identify your risks of developing a potentially deadly disease so you could prevent it or treat it sooner, wouldnt you?

A proactive genetic test can do just that. Caroline Ewart, Genetic Counselor in the Center for Precision Medicine and Genomic Health at St. Elizabeth Healthcare, says, Understanding your family tree is important for your future health. Genetics play a big role in what diseases we will develop in the future. The more we understand the family, the more you can proactively do to protect your health.

Many people dont consider genetic testing because they think it is too expensive, not accurate enough, or doesnt screen for the diseases that run in their family. Ewart is helping us bust some of the common myths of genetic testing.

Myth #1: Genetic Testing is Too Expensive

When proactive genetic testing started, it was very expensive, and only a few select laboratories across the country performed the testing. Today, genetic testing is very affordable. Many health insurance companies will provide some coverage for testing, and the laboratories now have a limit on what they can charge.

A proactive screening in the Center for Precision Medicine and Genomic at St. Elizabeth Healthcare is just $395. That includes an initial genetic counseling visit, coordination of blood tests, carrier status screening, and a comprehensive consultation discussing your results. Individuals with a Flexible Spending Account (FSA) or Health Savings Account (HSA) may be able to use these funds to pay for the cost of the screening.

Myth #2: Genetic Testing Only Finds Breast Cancers

Its true, when genetic testing was in its infancy, we only tested for BRCA1 and 2 genes which detect breast and ovarian cancers, says Ewart. But the tests today are far more sophisticated. We now test for over 100 different gene mutations looking for a range of diseases and cancers.

Inherited conditions the tests screen for, include:

Breast cancer

Cardiovascular diseases

Colorectal cancer

Cutaneous melanoma

Gastric cancer

Ovarian cancer

Pancreatic cancer

Renal cell cancer

Thyroid cancer

Myth #3: Genetic Testing Doesnt Help the Treatment of Diseases like Cancer

Genetic testing is used not only to proactively screen for certain diseases, but it is used to treat cancer as well.

If you have been diagnosed with cancer, the gene mutation may guide treatment. It can also help your team manage increased risks of developing other types of cancers, says Ewart.

More importantly, the results of proactive genetic testing can guide your healthcare teams recommendations for screenings of cancer and cardiovascular diseases. This may include starting screenings at an earlier age, increasing the frequency of screenings or suggesting more advance screenings.

By screening early, we can find the disease early, when it is most treatable, says Caroline.

Myth #4: Genetic Testing isnt Accurate

Ewart says, Certainly there are limitations to testing, but our process is more than just a blood test. By gathering a thorough family history we can determine your risk factors for developing certain diseases, even if a blood test comes back negative.

At St. Elizabeth Healthcare, if you are found to be at high risk or test positive for genetic cancers, you are referred to the Heredity Cancer Clinic to develop a plan for future cancer screenings. They may also recommend your family members be tested, so you can get a full picture of your familys health. St. Elizabeth has many types of genetic screenings. To find the one that best fits your needs, pleasestelizabeth.com/dna or call 859-301-GENE (4363).

View original post here:
Healthy Headlines: Four common myths about genetic testing and why they are not accurate - User-generated content

Read More...

18 Amish young people died suddenly; Mayo Clinic identified genetic problem believed to be responsible – LancasterOnline

January 20th, 2020 5:48 am

The Mayo Clinic has identified a genetic problem believed to have caused sudden death in 18 of 23 Amish young people who had it, according to media reports.

The study published recently in JAMA Cardiology said researchers studied two large Amish extended families that reported multiple sudden deaths, including four siblings with exercise-associated sudden deaths.

"With the help of new technology that wasn't around when they first started looking into the case, the team learned that these Amish children had all inherited the same genetic mutation from both of their parent," CNN reported.

Now that the problem has been identified, Popular Science reported, potential couples can be tested to see whether they are both carriers, and people who are at risk of sudden death because of the problem can have a defibrillator implanted.

One of the best-known medical facilities working with the Amish and other Plain community people to identify and treat genetic diseases is in Lancaster County the Clinic for Special Children in Strasburg.

The clinic wasn't involved in the study, according to spokeswoman Kelly Cullen. However, she said, lab director Dr. Erik Puffenberger checked its thousands of records for RYR2, the gene involved. None were affected, she wrote, only three were carriers of the gene, and only one of those people was local to Lancaster County, "demonstrating that the RYR2 genetic variant is very rare in our area."

Success! An email has been sent with a link to confirm list signup.

Error! There was an error processing your request.

However, she wrote, the clinic is planning to add RYR2 to the next version of its Plain Insight Panel, which screens for thousands of genetic variants known to cause problems across the Plain communities of North America.

See the article here:
18 Amish young people died suddenly; Mayo Clinic identified genetic problem believed to be responsible - LancasterOnline

Read More...

The Case Of Pamela Maurers Murder Went Cold For Decades, Then Genetic Sleuthing By Parabon Helped Crack It – CBS Chicago

January 20th, 2020 5:48 am

CHICAGO (CBS) Despite exhaustive work by detectives, the murder of Pamela Maurer was left unsolved for more than four decades. Last year, a relatively new form of genetic sleuthing began to put together the pieces of the mystery in a matter of days.

DuPage County investigators provided genetic material preserved from the Maurer crime scene to Maryland-based Parabon NanoLabs. Pamelas body was found in Lisle in January of 1976. She had been sexually assaulted and strangled. She was last seen alive the night before her body was found, when she told friends she was going to a restaurant to buy a soft drink.

First, Parabon, led by chief genetic genealogist CeCe Moore, used the DNA to create a snapshot genotypewhich predicts a persons physical traits, such as eye, skin and hair color, and even the shape of a face.

The composite created from that test looks remarkably similar to Bruce Lindahl, a suspected serial killer who police now say killed Maurer. Lindahl died in 1981.

But the testing didnt stop with just a picture. The hard work had only just begun.

Moores team used the DNA to reverse engineer Lindahls family tree.

Parabon loaded the DNA sample from the Maurer crime to a website called GEDmatch and began a form of genetic treasure hunting. GEDMatch is a site where users can upload their genetic testing results, done by companies like 23AndMe and Ancestry.

Typically, Moore said, they find similar DNA from distant cousins of a suspect and build back from there.

We are looking just for people who are second, third, fourth, fifth cousins and beyond, Moore said. Typically we are not getting close matches to close family members.

Basically, Parabon is reverse engineering the family tree of the suspect based on who they are sharing DNA with, Moore said.

Moore said she found multiple distant cousins that led to Lindahl, up to 20 matches and put those puzzle pieces together.

It is almost never a single match that leads to an identity. Its a group of matches to see how they all connect to each other.

My work, and my teams work is really about providing answers to these families for years and decades, Moore said.

She said part of the hunt is luck. In this case, the data allowed them to find a suspected match to Lindahl in a few days.

But Parabons work didnt solve the case. Detectives still needed more proof. So, they got a court order to exhume Lindahls body and extract DNA from his remains.

The result was a match.

The odds of the DNA belonging to somebody else are 1 in 1.8 quadrillion, DuPage County States Attorney Robert Berlin said this week.

This was the second case Parabon has done in Illinois, but the first in the Chicago area.

Last year, Moores work led to murder charges against Michael Henslick, who police say killed Holly Cassano. She was found fatally stabbed in her home in Mahomet, Ill., on Nov. 2, 2009.

That case is expected to go to trial next month, Moore said. Parabon has so far worked on 93 cases with police across the country in the past two years. The most famous charges against the suspected Golden State Killer, Joseph James DeAngelo.

Critics find the practice controversial and a potential invasion of private DNA data. Moore says the benefit to the public, ensuring that killers are put behind bars, and the fact that families get some resolution, far outweigh those concerns.

I feel that the good that has been done is really immeasurable to public safety, Moore said.

Lindahl died at age 28 in 1981 after he bled to death while stabbing another victim, Charles Huber. The coroner said his knife wounds were accidentally self inflicted.

RELATED: Those Who Remember Lindahl Say He Gave Them The Creeps

Police now say he may have killed at least two other women.

Lindahl was charged with raping Deborah Colliander, who manged to escape from the attack. However, two weeks before Lindahls trial, Colliander disappeared after leaving her job at a hospital.

The case against Lindahl was dropped.Collianders body was found on April 28, 1982in a field on Oswego Township.

Investigators also think Lindahl may have something to do with the disappearance of Deborah McCall, a student at Downers Grove North. She was last seen alive in November 1979. Photos of her were found in one of Lindahls residences.

And there may be other victims in the 1970s and before his death, police said. The new evidence will be used to open additional investigations.

Investigators set up two tip lines: (630) 407-8107 (DuPage States Attorney) and (630) 271-4252 (Lisle police).

Read the rest here:
The Case Of Pamela Maurers Murder Went Cold For Decades, Then Genetic Sleuthing By Parabon Helped Crack It - CBS Chicago

Read More...

Donor-conceived people lobby UN for access to their genetic heritage – UNSW Newsroom

January 20th, 2020 5:48 am

Giselle Newton, a PhD research student at UNSW, is one of 16 donor-conceived and surrogate-born people from around the world who are leading a renewed push to change laws which govern their access to information about their genetic heritage.

For the first time, the group told their own stories at a historic visit to the United Nations to mark the 30-year anniversary of the Convention for the Rights of the Child in Geneva on November 19.

They presented their five recommendations* to the Human Rights High Commissioner Michele Bachelet, and received a standing ovation from the audience.

We highlighted the consequences of ignoring the voices of those most affected by these practices, Ms Newton says. Donor-conceived people are experts on this issue and our voices need to be listened to and acted upon.

International Social Services representative Mia Dambach led the workshop on biotechnology at the UN, and says there is an urgent need for the development of global standards.

It is hoped that this will not be the last time the voices of those most affected are heard representing as many experiences as possible, Ms Dambach says.

Ms Newton was conceived in the Northern Territory by sperm donated in Western Australia, before being born in NSW.

She says her parents did the right thing by telling her at a very young age that she was donor-conceived.

From day dot, its really important for children to know they were donor-conceived, Ms Newton says. And that they have the ability to contact donors and donor-conceived siblings.

Laws

In Australia, laws differ between the states.Victoria is leading with legislation implemented in 2017 that allows all donor-conceived people the chance to retrospectively access information about their biological parents.

It would be good if other states really pull up their socks and follow suit, Ms Newton says.

But in NSW, recent changes to legislation allow donor-conceived children born after January 1, 2010 the ability to track down their biological parent(s), once they turn 18. Those born before this date can only access non-identifying markers such as the ethnicity, physical characteristics, medical history, and the sex and year of each of the donors offspring.

In WA, once a donor child turns 16, records relating to his or her lineage are open for them to access. But for those born before 2004, they need to have the donors permission before they can obtain the missing pieces to their biological puzzle.

What Ms Newton and others like her want is the power to access information about their identity and origins including information about their donors and donor-conceived siblings.Being disconnected from your biological history can have drastic consequences in terms of identity, she says.

It is this emotional element that US doctor William Pancoast did not foresee when he made the first successful experiment by artificially inseminating a woman with the sperm of one of his most attractive medical students in 1866.

UNSW PhD study

While estimates have suggested that there are between 20,000-60,000 donor-conceived people in Australia, Ms Newton says that there has been very limited empirical research that explores life as a donor-conceived adult in Australia.

In her doctoral thesis at UNSWs Centre for Social Research in Health, she will examine what services and support are available to donor-conceived people with a particular focus on the role of peer support in online and offline contexts.

I am really fascinated by the idea of how connection with peers can contribute to a sense of belonging, she says.

UNSW Associate Professor Christy Newman has highlighted the importance of Ms Newtons research for the support needs of donor-conceived adults. She hopes it will help inform policy and practice responses to this increasingly growing group of people in Australia and around the world.

Ms Newton will be recruiting donor-conceived people to participate in a national online survey and interviews in early 2020.

(To participate or find out more about the study)

An international concern

Netherlands-based Joey Hoofdman was among those who participated at the UN conference in Geneva. Mr Hoofdman found out he has at least 75 half-siblings via the doctor who treated his parents for fertility problems in the 1980s. The 32-year-old only discovered in 2017 that he was donor-conceived.

Mr Hoofdman says he blames his biological father for having crossed a medical-ethical boundary by using his own sperm during a time when there was insufficient supervision and a lack of regulation.

We need to make agreements on an international level so we can prevent this from ever happening again.

*Recommendations

Ms Newton, Mr Hoofdman and others put forward the following to the UN:

1) Ensure the right of donor-conceived and surrogate-born children to access information about their identity and origins regardless of when these children were conceived and born, and to preserve relations with their biological, social and gestational families.

2) Ensure that comprehensive and complete records of all parties involved in the conception of the child be held by the State in perpetuity for future generations.

3) Respect and promote the full and effective enjoyment of all the rights of donor-conceived and surrogate-born children in both the immediate and longer terms.

4) Ensure that the best interests of the child be the paramount consideration in all relevant laws, policies and practices and in any judicial and administrative decisions. This requires a best interests assessment pre-conception on a case-by-case basis.

5) Prohibit all forms of commercialisation of gametes, children and surrogates including, but not limited to, the sale and trafficking in persons and gametes.

Go here to see the original:
Donor-conceived people lobby UN for access to their genetic heritage - UNSW Newsroom

Read More...

BTYSTE 2020: From eco-friendly dollhouses to the genetics of clever dogs VIDEO – Siliconrepublic.com

January 20th, 2020 5:48 am

We visited theBT Young Scientist and Technology Exhibition again this year, getting the chance to chat to some of the countrys brightest students.

There were project posters stretching to all corners of the main hall at the RDS, filled with excited participants waiting for their visit from the judging panel.

Hugh Murtagh from Coliste Mhuire in Westmeath took us through hisA-Ok project a discreet wristband that students with autism can wear to let their teacher know if theyre feeling overwhelmed at school.

I have autism and I know just how hard it is to try and focus in class when you feel overwhelmed. I want to try and help people like me and people who also have autism, he said.

We also learned about an eco-powered dollhouse with the potential to teach children about climate action, how mental health can be impacted by climate change, and whether genetics affects how clever a dog breed is.

>> READ MORE

Words by Lisa Ardill

More:
BTYSTE 2020: From eco-friendly dollhouses to the genetics of clever dogs VIDEO - Siliconrepublic.com

Read More...

Page 718«..1020..717718719720..730740..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick